CHARACTERIZING THE EFFECTS OF BOTH SYNTHETIC AND NATURAL INHIBITORS ON THE FUNCTION OF HOLOCARBOXYLASE SYNTHETASE AND LIPID METABOLISM by Cordonier, Elizabeth
University of Nebraska - Lincoln
DigitalCommons@University of Nebraska - Lincoln
Nutrition & Health Sciences Dissertations & Theses Nutrition and Health Sciences, Department of
Summer 5-2015
CHARACTERIZING THE EFFECTS OF
BOTH SYNTHETIC AND NATURAL
INHIBITORS ON THE FUNCTION OF
HOLOCARBOXYLASE SYNTHETASE AND
LIPID METABOLISM
Elizabeth Cordonier
University of Nebraska-Lincoln, elizabeth.cordonier@huskers.unl.edu
Follow this and additional works at: http://digitalcommons.unl.edu/nutritiondiss
Part of the Nutrition Commons
This Article is brought to you for free and open access by the Nutrition and Health Sciences, Department of at DigitalCommons@University of
Nebraska - Lincoln. It has been accepted for inclusion in Nutrition & Health Sciences Dissertations & Theses by an authorized administrator of
DigitalCommons@University of Nebraska - Lincoln.
Cordonier, Elizabeth, "CHARACTERIZING THE EFFECTS OF BOTH SYNTHETIC AND NATURAL INHIBITORS ON THE
FUNCTION OF HOLOCARBOXYLASE SYNTHETASE AND LIPID METABOLISM" (2015). Nutrition & Health Sciences
Dissertations & Theses. 58.
http://digitalcommons.unl.edu/nutritiondiss/58
 
 
CHARACTERIZING THE EFFECTS OF BOTH SYNTHETIC AND NATURAL 
INHIBITORS ON THE FUNCTION OF HOLOCARBOXYLASE SYNTHETASE AND 
LIPID METABOLISM  
by 
Elizabeth Cordonier 
 
 
A DISSERTATION  
 
  
Presented to the Faculty of  
The Graduate College at the University of Nebraska 
In Partial Fulfillment of Requirements  
For the Degree of Doctor of Philosophy  
 
Major: Interdepartmental Nutrition Program 
Under the Supervision of Professor Janos Zempleni 
Lincoln, Nebraska 
May, 2015 
  
CHARACTERIZING THE EFFECTS OF BOTH SYNTHETIC AND NATURAL 
INHIBITORS ON THE FUNCTION OF HOLOCARBOXYLASE SYNTHETASE AND 
LIPID METABOLISM   
 
Elizabeth Cordonier, Ph.D. 
University of Nebraska, 2015 
Advisor: Janos Zempleni 
The central theme of this dissertation explores enzyme inhibition, through the use of both 
synthetic and natural occurring inhibitors of three biotin-associated enzymes; the 
mammalian biotin ligase, holocarboxylase synthetase(HLCS), and acetyl-CoA 
carboxylases 1 and 2 (ACC1 and 2), whose activity is dependent on biotinylation by 
HLCS, and are involved in fatty acid synthesis and regulation of beta-oxidation, 
respectively.  No null HLCS individual has ever been reported and individuals with 
inherited mutations in the HLCS gene, which render it incapable of biotinylating 
carboxylases, exhibit varying degrees of symptoms associated with multiple carboxylase 
deficiency. Little is known with regard to the reaction mechanism and structure of HLCS.  
The first chapter of this dissertation focuses on the characterization of a novel class of 
HLCS inhibitors, the biotin-5’-AMP analogs, -ketophosphonate and -
hydroxyphosphonate, that could be of potential use as an analytical tool in studies of 
HLCS-biotinylation between the well-known carboxylase targets and novel targets in 
other proteins.  Adapting an existing in vitro protocol in our laboratory, the inhibitors 
were demonstrated to be competitive inhibitors of HLCS. We extend these studies of 
  
HLCS in the next chapter by identifying resveratrol compounds as natural inhibitors of 
HLCS in vitro which protect Drosophila melanogaster brummer mutants from fat mass 
accumulation. The third chapter focuses on the effects of dual inhibition of ACC1 and 
ACC2 on adipocyte differentiation of 3T3-L1 cells. We report on the effects of Soraphen 
A, a natural occurring polyketide derived from Sorangium cellulosum, which targets the 
biotin carboxylase domain of the eukaryotic ACCs. We demonstrate that Soraphen A 
prevents adipogenic gene expression and lipid accumulation in 3T3-L1 cells suggesting 
dual inhibitors of ACC1 and ACC2 may be an effective strategy to prevent fat 
accumulation. In conclusion, we have demonstrated the inhibition of HLCS with both 
synthetic and natural compounds, and that ACC1 and ACC2 inhibition alters lipid 
metabolism in adipocytes. 
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The first part of this introduction will focus on the biological significance of 
holocarboxylase synthetase (HLCS), current understanding of its catalytic mechanism and 
a discussion of inhibitors developed against its bacterial homolog BirA.  The second part of 
this section will introduce the acetyl-CoA carboxylase (ACC) enzymes, Soraphen A, a dual 
ACC1/ACC2 inhibitor, and ACC inhibition as a potential inhibitor of adipocyte 
differentiation.  
I.HLCS 
Background and Significance 
The HLCS gene is located on chromosome 21q22.13 and contains 18 exons.  The enzyme 
holocarboxylase synthetase (HLCS) is generated by a 6019 bp gene which consists of 726 
amino acids and Mr 80,629. Holocarboxylase synthetase (HLCS) catalyzes the attachment 
of biotin to five carboxylase proteins.  The five biotin-dependent carboxylases are 
propionyl-CoA carboxylase (PCC), methylcrotonoyl-CoA carboxylase (MCC), pyruvate 
carboxylase (PC), and acetyl-CoA carboxylase 1 and 2 (ACC1 and 2)[1]. ACC1 is located 
in the cytosol, ACC2 is anchored in the outer mitochondrial membrane and the remaining 
three enzymes reside within the mitochondria [2].  These enzymes are involved in odd-
chain fatty acid metabolism, leucine catabolism, gluconeogenesis and fatty acid synthesis, 
and regulation of fatty acid oxidation, respectively[1].  Additionally, HLCS-dependent 
methylation of the nuclear co-repressor N-CoR and the histone methyltransferase EHMT1 
is partially responsible for the formation of a multiprotein gene repression complex[3, 4]. 
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Consistent with its importance in intermediary metabolism, HLCS is essential for survival 
as no living HLCS null individual has been reported.  Additionally, mutations and single 
nucleotide polymorphisms in the HLCS gene result in decreased HLCS activity resulting in 
abnormal gene regulation and metabolic abnormalities due to the inability of HLCS to 
biotinylate carboxylase proteins essential to intermediary metabolism[5, 6]. These 
mutations are inherited in an autosomal recessive pattern and the disorder manifests in 
infancy, with numerous complications including skin rash, hair loss, difficulties in 
breathing or eating, and lack of energy. Treatment with pharmacological doses of biotin is 
necessary for the entirety of an affected person’s life [7].      
Much of what is known about HLCS structure and function comes from studies of its 
bacterial homolog BirA, the biotin protein ligase(BPL) of Escherichia coli, which has 21% 
sequence similarity to HLCS [8].  BirA catalyzes the attachment of biotin to the acetyl-coA 
carboxylase subunit, biotin carboxyl carrier protein (BCCP).  In addition to its function as a 
biotin ligase, BirA also serves as a repressor of transcription initiation [9]. In both 
situations, biotinyl-5’-AMP, serves as the reaction intermediate[9, 10]. Functional 
complementation studies in E.coli demonstrate that HLCS clones are capable of 
biotinylating BCCP, in E. coli birA104 cells, mutants defective in biotin ligase [11]. These 
studies indicate that BirA and HLCS share a similar catalytic mechanism. 
Catalytic mechanism of HLCS 
 HLCS-dependent biotinylation occurs via a condensation reaction involving two steps.  In 
the first step, biotin is activated by ATP hydrolysis generating the mixed anhydride, biotin-
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5’-adenosine monophosphate (Bio-5’-AMP)(1). Bio-5’-AMP serves as an acylating agent, 
covalently linking an amide bond between the valeric acid side chain of the 
tetrahydrothiophene ring in biotin and the epsilon amino group of a target lysine in the 
carboxylase protein (2)[12].  This lysine residue is found within a biotin acceptor sequence 
(AMKM) whose residues allow the biotinylated residues to swing the carboxyl group to the 
receiving substrate from the site of activation.  
 
Fig 1. Catalytic mechanism of HLCS 
(Reprinted with permission from Bioorganic and Medicinal Chemistry Letters, 2014, 
24, 5568-5571) 
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 HLCS structure-current understanding 
Limited structural knowledge of HLCS is available due to the inability to generate a high-
resolution structure of HLCS[13]. Three structural domains are predicted in the HLCS 
protein, one in the N-terminus(amino acids 166-290) and two in the C-terminus (amino 
acids 460-669 and 670-726) and 349 residues of the C-terminal region has been shown to 
be minimally functional [14].  This C-terminal portion is highly conserved across all 
species and is required for the cross-species biotinylation of BCCP and p67, the last 67 
amino acids within propionyl-CoA carboxylase [14, 15].  The N-terminal region is not 
conserved among biotin protein ligases and the N-terminus of HLCS has not been 
implicated in transcriptional regulation unlike its bacterial counterpart which contains a 
DNA-binding motif within its N-terminus [11, 13].  The N-terminal region has been 
implicated in catalysis even though it’s not necessary for HLCS activity.  HLCS with C- 
and N-terminal deletions evaluated for their ability to catalyze biotinylation of human and 
bacterial substrates after expression in E.coli revealed that the region between Leu166 and 
Arg290 is necessary for catalysis while smaller deletions (the first 58, 80 or 165 amino 
acids of the N-terminus) were able to restore growth in E.coli and biotinylate both p67 and 
BCCP87, the last 87 residues of BCCP [14].  The authors speculate that when this region 
encompassing Leu166 and Arg290 is removed it blocks the active site, whereas removing 
the whole domain restores activity.    
Individuals with mutations in either the C- or N-terminus of the HLCS gene have been 
reported [6] and this information has provided some additional insight into the catalytic 
mechanism of HLCS. These mutations are divided into two groups. The Km mutants are 
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those in which HLCS has a decreased affinity for biotin and pharmacological doses of 
biotin are successful in treating patients with these mutations. The activity of the HLCS 
enzyme is compromised in Vmax mutants, but successful treatment of MCD with biotin 
supplementation varies.  The majority of amino acid substitutions that cluster around the 
biotin and ATP sites in the C-terminal catalytic portion are those that result in an increased 
Km. The most notable of these substitutions occurs in Arg508, a highly conserved residue 
in all BPLs, Gly518 which lies in the biotin binding pocket, and Asp571 which positions 
Lys579 in the AMP binding pocket [16].  Substitutions at Arg183, Leu216 and Leu237, all 
map to the N-terminus and are grouped as Vmax mutants because the patients who have 
these mutations show variable responses to biotin treatment.  Five of seven patients with 
the Leu216Arg mutation died between 3 days and 3 years despite three of the patients 
being administered biotin after presenting with severe acidosis[17]. Despite being on either 
40mg or 80mg/day of biotin treatment, individuals with the Leu237Pro mutation show 
delays in development and lower IQ even though other symptoms were resolved [18].    
Inhibitors of BirA               
A couple of non-hydrolyzable analogs of biotinyl-5’-AMP have been developed as 
inhibitors against the bacterial biotin protein ligases to study their reaction mechanism. 
These non-hydrolyzable analogs, an ester and a sulfamoyl derivative, were used to study 
allosteric regulation of BirA [9].  The ester derivative biotinol-AMP, inhibits biotin transfer 
to the acceptor protein through tight binding to the Escherichia coli biotin repressor ( 
KD=1.5  0.2 nM) [19].   Inhibitors against Staphylococcus aureus and Mycobacterium 
tuberculosis have been developed as a potential novel class of antibiotics [10, 20]. Soares 
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de costa et al. reported on the selective inhibition of S. aureus BPL over HLCS by linking 
biotin to an adenosine with a 1,2,3 triazole.  The biotin 1,2,3 triazole demonstrated potent 
inhibition (Ki=90nM) of BPL from S. aureus with >1100 fold selectivity over the human 
homologue. Additionally, it showed anti-microbial activity against S. aureus while 
showing no toxicity in HepG2 cells[10].  A bisusbtrate inhibitor of mycobacterial protein 
ligase (MtBPL) was characterized and described previously[20]. Its design was similar to 
that of the sulfamide derivative but the 5’-oxygen atom was replaced with a nitrogen atom. 
The inhibitor binds approximately 1700-fold more tightly to MtBPL than biotin and has an 
IC50=135 ± 9 nM.  It was effective at inhibiting growth of multi-drug resistant and 
extensively drug-resistant at 0.16-0.625 M concentrations and was ineffective against 
other microbial species and non-cytotoxic to mammalian cells [20].  
Naturally occurring inhibitors of HLCS 
To date, there have not been any naturally occurring compounds in food products that have 
been found to inhibit HLCS activity. We received a library of extracts that we screened for 
HLCS activity in vitro.  It was initially observed that grape leaf extracts potently inhibited 
HLCS activity in vitro.  Resveratrol has been shown to delay or prevent heart disease, 
cancer, diabetes, pathological inflammation, and even obesity [21].  
Objectives  
The objective of these studies was to identify and characterize synthetic and naturally 
occurring compounds that inhibit HLCS, providing a tool to study HLCS biotinylation 
events in distinct cellular structures.  
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II. ACC1 and ACC2 
Background and significance 
Acetyl-CoA is the starting compound of fatty acid synthesis [22] and is formed in the 
mitochondria from the decarboxylation of pyruvate. It is subsequently transported as citrate 
via the citrate pyruvate shuttle to the cytosol where it is reconverted to acetyl-CoA by ATP 
citrate lyase. The rate-limiting step of fatty acid synthesis, carboxylation of acetyl-CoA to 
malonyl-CoA is catalyzed by acetyl-CoA carboxylase (ACC). The mammalian ACC 
enzymes consist of a single polypeptide chain encoding a biotin carboxylase(BC), biotin 
carboxyl carrier protein(BCCP), and a carboxyltransferase (CT) domain [23]. The bacterial 
and yeast ACCs exist as dimeric enzymes and other eukaryotic ACCs are believed to exist 
as either dimers or oligomers [24]. In addition to malonyl-CoA serving as the carbon donor 
in fatty acid biosynthesis [25], it is a potent inhibitor of the carnitine palmitoyl-CoA shuttle 
system.  The rate limiting step of β-oxidation, transfer of an acyl group of a long-chain 
fatty acyl CoA from coenzyme A to L-carnitine to form an acyl carnitine is catalyzed by 
carnitine palmitoyltransferase I (CPT1) [26, 27] (Figure 2).  There are two ACC genes, 
ACC1 or ACC, and ACC2 or ACC and the catalytic mechanism is the same in the two 
enzymes.  
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Figure 2. ACC1 and ACC2 in liver, adipose tissue, and skeletal muscle. In liver, FA are 
converted to acyl-CoA; glucose undergoes glycolysis and generates pyruvate, which is 
oxidized in the mitochondria through pyruvate dehydrogenase to acetyl-coenzyme A (acetyl-
CoA). Acetyl-CoA is also produced through amino acid metabolism. Acetyl-CoA is oxidized 
through the citric acid cycle to yield energy, H2O, and CO2 or it is converted to citrate, which 
exits to the cytosol and generates acetyl-CoA through ATP citrate lyase (ACLY) or 
carnitine/acetyl-CoA (CAT), which exits from the mitochondria to the cytosol. In the cytosol 
acetyl-CoA is carboxylated to malonyl-CoA by ACC1 and utilized through fatty acid synthase 
(FAS) reactions to generate palmitate, which is utilized in the synthesis of triglycerides (TG) 
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and VLDL. Also, acetyl-CoA is carboxylated by ACC2 at the mitochondrial membrane to 
form malonyl-CoA, which inhibits the CPT1 and reduces acyl-CoA transfer to mitochondria 
for β-oxidation. Basically comparable reactions, with appropriate modifications, occur in 
adipose and muscle tissues.  
(Reprinted with permission from the Journal of Lipid Research, 2009, S138-S143) 
The catalytic mechanism is dependent on the prosthetic group biotin bound to the BCCP 
and proceeds in two steps. In the first step, the N1 atom in the ureido group of biotin is 
carboxylated by biotin carboxylase.  Bicarbonate serves as the carboxyl group donor and 
the reaction is driven by ATP hydrolysis. In the second step, the activated carboxyl group 
is transferred from the N1 atom of biotin to the methyl group of acetyl-CoA to produce 
malonyl-CoA, by the carboxyltransferase domain [23, 28].   Biotin can translocate between 
the active sites of the BC and CT domain due to its position at the end of a ‘swinging arm’, 
which is made up of 8 methylene groups and 10 rotatable single bonds that forms between 
the backbone of the BCCP and the bicyclic ring of biotin (Figure 3)[28].  
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Figure 3. Catalytic mechanism of acetyl-CoA carboxylase enzymes 
A single gene encoding the multifunctional polypeptide (265 kDa) of ACC1 maps to 
chromosome 17q12. ACC1 is found in the cytoplasm and is primarily expressed in 
lipogenic tissues such as adipose tissue, mammary gland tissue and the liver Malonyl-CoA 
produced from ACC1 feeds into fatty acid synthesis [29].      
ACC2 was first discovered in rat heart and is localized to chromosome 12q23 [30].  Human 
liver ACC2 cDNA nucleotide sequence has an open reading frame of 7,449 nucleotides, 
encoding 2,483 amino acids to give a calculated molecular weight of ~280kDa [31]. 
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There are 114 additional amino acids at the N-terminus of ACC2 with hydrophobic 
residues making up the first several amino acids, suggesting that ACC2 is a membrane-
associated enzyme [31]. Affinity-purified anti-ACC2 antibodies and immunocytochemical 
methods demonstrated that anti-ACC2 is associated with the mitochondrial membrane [2]. 
Expression of ACC2 is primarily in the heart and skeletal muscle [29].   
Regulation of ACC 
ACCs are regulated at both the transcriptional and post-translational levels.  At the 
transcriptional level, multiple promoters exist for the mammalian ACCs and the use of 
various promoters results in modulation of the N-terminal sequence of the encoded proteins 
due to alternative splicing at the 5’end. An alternative trancript of ACC1 that results from 
the PIII promoter lacks the phosphorylation site of AMPK[32].  A transcript lacking the N-
terminal sequence which targets ACC2 to the mitochondrial membrane is a product of 
alternative splicing [29]. Transcription factors such as sterol regulatory element binding 
proteins (SREBP1a and SREBP1c) and carbohydrate response element binding protein 
(ChREBP) activate ACC gene expression upon feeding of a high carbohydrate diet either 
in dependently or independently of insulin action, respectively [33].  PGC-1, a 
peroxisome proliferator-activated receptor  coactivator-1 regulates SREBP-1c expression 
and has crucial roles in lipogenesis[34].  
At the post-translational level, citrate, long chain acyl-CoAs, and AMPK play roles in 
regulating ACC activity.  Citrate promotes polymerization of ACCs and its subsequent 
activation. Long chain acyl-CoAs, such as palmitoyl-CoA have an opposing effect; they 
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bind tightly to ACC (Ki= 5.5nM) preventing its polymerization[35].  Both ACCs can be 
phosphorylated by AMPK under physiological conditions, inhibiting their activity through 
reductions in Vmax [36].  AMPK phosphorylates serine residues located next to the BC 
domain, Ser79 in ACC1 and Ser218 in ACC2, and this inhibition may be enough to block 
activity of the enzymes[36]. 
Effects of ACC animal models on diet-induced obesity and diabetes 
Interest in ACCs as therapeutic targets was generated with the publication of several 
studies reporting on the effects of knocking out ACC2 in vivo [37, 38]. Mutant Acc2-/- 
mice fed a high-fat/high carbohydrate diet or high-fat diet for 4 months, had lower body 
weight than their wild type cohorts.  The Acc2-/- mice were protected from diabetes as 
evidenced by insulin and glucose levels being maintained within a normal range and 
significantly lower than WT mice. Palmitate oxidation in soleus muscle was decreased 
upon stimulation with insulin while fatty acid oxidation was unchanged in soleus muscle of 
ACC2-/- mice. Additionally, the amount of triglyceride in the liver of ACC2-/- mice fed a 
standared diet was lower than those of WT mice. However, fatty acid synthase activity and 
malonyl-CoA levels were the same in liver extracts of the mutant and wild type mice [37].  
Another study found that Acc2-/- mice had increased total energy expenditure, and 
respiratory quotient (RQ) profiles that suggested an increase in fat and carbohydrate 
oxidation.  Hyperinsulinemic-euglycemic clamp experiments revealed that plasma insulin 
concentrations were 26% lower in the Acc2-/- mice indicating increased insulin clearance 
while glucose uptake in the skeletal muscle and white adipose tissue were increased by 
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66% and 100% in these mice, suggesting increased insulin sensitivity. Decreased 
triglycerides and long-chain acyl-CoAs in the liver and skeletal muscle of Acc2-/- mice 
were observed in the high-fat-fed Acc2-/- mice as compared to high-fat-fed WT mice [38].   
However, other studies of ACC2-/- knockout models contradict the results obtained by 
Abu-Elheiga.  Mice with global knockout of ACC2 had similar body weights and food 
intake, as compared to wild-type controls [39, 40].   These ACC2-/- deficient had 
decreased malonyl CoA levels in cardiac and skeletal muscle and increased fatty acid 
oxidation(~57%) in isolated soleus muscle. Accumulation of triglyceride in the liver and 
muscle and overall energy expenditure was the same in both WT and ACC2-/- mice while 
glycogen stores were elevated in muscle and there was increased use of glucose for lipid 
synthesis. Additionally, there was no difference in adiposity or body weight between WT 
and ACC2-/- deficient mice challenged with a HFD  [39]. 
A null ACC1 mutation is embryonically lethal in mice [41].  Liver-specific knockouts of 
ACC1 (LACC1-/-) generated by Kusunoki’s and Wakil’s groups have also produced 
controversial results [42, 43]. There were no differences in fatty acid synthesis of malonyl-
CoA levels in Kusonoki’s LACC1-/- mice liver samples compared to WT mice while liver 
samples from Wakil’s LACC1-/- produced the opposite effects [42, 43].  There exists the 
possibility that either ACC enzyme can compensate for the other indicating the necessity of 
inhibiting both ACC enzymes may be required to alter energy balance. A number of dual 
ACC1/ACC2 inhibitors have been developed, and reviewed by Bourbeau and Bartberger 
[44]. 
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Soraphen A, a nonselective potent inhibitor of ACCs 
Soraphen A(SA), a macrocylic polyketide derived from the soil-dwelling myxobacterium 
Sorangium cellulosum that displays antifungal activity. Biochemical studies in yeast 
demonstrated that SA inhibited the glycerol biosynthesis pathway necessary for growing 
cells, but not resting cells.  Subsequent genetic studies showed that ACC1 was tightly 
linked to SA resistance and that ACC activity was inhibited by SA treatment [45, 46]. 
Structural studies demonstrate that the compound acts by binding to the BC domain of the 
ACC enzymes preventing its dimerization or oligomerization of eukaryotic ACCs [23].  SA 
inhibits ACCs at concentrations as low as 1nM [23].   
In addition to working as a fungicide, SA has also been shown to work against mammalian 
ACCs.  In LNCaP and PC-3M prostate cancer cells, and liver HepG2 cells, SA stimulates 
fatty acid oxidation and inhibits fatty acid synthesis [47, 48].  The inability to synthesize 
phospholipids, the major end product of fatty acids in cancer cells was accompanied by a 
decrease in proliferation and in viability, reaching 50% and 70% viability in LNCaP and 
PC-3M cells, respectively [47]. Induction of apoptosis is responsible for the death of 
LNCaP cells while autophagy contributed to PC-3M cell death.  The phospholipid content 
was unaltered in premalignant BPH-1 cells and cell viability was unaffected in 
nonmalignant fibroblasts and BPH-1 cells. Supplementation with palmitate suppresses the 
cytotoxicity of SA treatment in LNCaP and PC-3M cells [47].  Additional studies in 
HepG2 and LNCaP cells showed that SA also blocks fatty acid elongation of products 
derived from exogenous saturated and unsaturated fatty acids, and de novo lipogenesis 
leading to an accumulation of unsaturated fatty acids derived from polyunsaturated and 
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saturated precursors.  This inhibitory effect of SA could not be abrogated by 
overexpression with the fatty acid elongases, Elovl5 and Elovl6 [48]. 
To date, one animal study has observed the effects of SA on high fat diet-induced insulin 
resistance in mice. Male C57Bl/6 mice fed a high fat diet supplemented with SA had 
reduced weight gain, adipose tissue, fasting plasma insulin levels, and beta-
hydroxybutyrate as compared to mice fed high fat diets without SA supplementation and 
levels comparable to those of the control.  Glucose infusion rate during hyperinsulinemic 
euglycemic clamp experiments was higher in mice fed diets supplemented with SA as 
compared to those fed a high fat diet. Lipogenic gene expression was unchanged between 
treatment groups in the liver, adipose tissue, and skeletal muscle; the only difference was 
an increase in fatty acid synthase (FAS) in the liver of the high fat fed mice, including 
those supplemented with SA [49].  Malonyl-CoA is converted to fatty acids by FAS.    
Adipocyte differentiation and fat mass expansion 
The hypothesis that ACC inhibition prevents adipocyte differentiation has yet to be tested.  
Lodhi et al. reported on the effects of a knockdown of FAS in adult adipose tissue and 
PexRap, a protein required for adipogenesis and alkyl ether lipid transcriptional activity. 
Fat specific knockout of FAS in mice lessened diet-induced obesity and increased brown 
fat-like cells in these mice. Knockout of PexRap resulted in a similar decrease in diet 
induced obesity in PexRap knockout mice [50].  Because ACCs are upstream of FAS in the 
fatty acid biosymthesis pathways, it’s possible that dual inhibition of ACC1 and ACC2 
may prevent adipocyte differentiation (Figure 4).  
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Figure 4. Disruption of FAS blocks adipogenesis and promotes thermogenesis. FAS 
synthesizes lipids that serve as substrate for PexRap which generates alkyl ether 
lipids which are potential endogenous PPAR ligands. ACCs produce malonyl-CoA 
that is converted into fatty acids by FAS.    
(Reprinted with permission from Cell Metabolism, 2012, 16, 189-201) 
Adipocytes are specialized eukaryotic cell types that contain organelles called lipid 
droplets, which store energy as fat. The number of adipocytes is set in childhood and 
adolescence with approximately 10% of adipocytes turning over in adult human adipose 
tissue every year. [51].  When energy intake exceeds energy expenditure, fat mass expands 
primarily through hypertrophy of existing adipocytes and through hyperplasia (occurs only 
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in children and adolescents) [51].  The stromal vascular fraction of adipose tissue contains 
pluripotent mesnchymal stem cells, which are capable of differentiating into adipocytes, 
osteoblasts, myocytes, and chondrocytes [52].  These cells differentiate into adipocytes 
when host animals undergo lipodystrophy or high fat feeding, states that are conducive to 
fat mass expansion [52].     
Adipogenesis or adipocyte differentiation is a highly regulated process that is divided into 
two phases, determination and terminal differentiation.  The determination phase is defined 
by the conversion of the stem cell into a pre-adipocyte; these cells are unable to 
differentiate into another cell type but remain indistinguishable from their stem cell 
precursors.  When the pre-adipocyte starts taking on features of a mature adipocyte, this is 
the terminal differentiation phase [53]. One of the hallmark features of a mature adipocyte 
is the accumulation of triglyceride, which is stored in lipid droplets. De novo lipogenesis is 
associated with triglyceride accumulation as measured by incorporation of 
14
C-acetate in 
3T3-L1 cells.  Most of 
14
C-acetate incorporation is directed into triglyceride synthesis 
(~80%) with 9 and 6% incorporated into free fatty acids and phospholipids, respectively 
[54].  
The other hallmark of adipocyte differentation is the expression and activation of 
peroxisome proliferator-activated receptor gamma(PPAR) which is crucial for 
adipogenesis and maintenance of differentiated adipocytes.  In its absence, no other factor 
is capable of promoting adipogenesis [53].  De-differentiation of adipocytes with loss of 
lipid accumulation and decreased expression of adipocyte markers occurs when dominant 
negative PPAR is introduced into mature 3T3-L1 adipocytes [55].  Two isoforms, 
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PPAR1 and PPAR2 are both induced during adipogenesis but PPAR2 promotes 
adipogenesis more efficiently [56].   The DNA binding domain of PPAR binds to a 
consensus sequence, a direct repeat of AGGTCA separated by a single nucleotide, known 
as a PPAR response element (PPRE) in its target genes, with retinoid-X-receptor  
(RXR) to induce transcription of target genes [57]. Activation of PPAR is dependent on 
cAMP production during early adipogenesis but ligand activation of PPAR is not required 
for PPAR-dependent gene expression in mature adipocytes [58]. Even though PPAR 
activation is dependent on cAMP production, an endogenous ligand of PPAR has 
remained elusive [53].  
PPAR induces the expression of genes involved in lipogenesis, lipolysis, and insulin 
sensitivity during adipocyte differentiation.  These genes include fatty acid binding protein 
(FABP4, also known as adipocyte protein, aP2), glucose transporter GLUT4, perilipin, 
lipoprotein lipase (LPL), and the secreted factors, leptin and adiponectin [52].  FABP4 is 
an intracellular binding protein transporting fatty acids into the nucleus and to and from 
lipid droplets.  It has been found that FABP4 may underlie transcriptional activation of 
PPAR through continuous nucleocytoplasmic shuttling [59].  Glucose transport into 
adiopcytes is facilitated by GLUT4 [60]. Perilipin, a protein associated with the surface of 
lipid droplets protects against the action of lipases and regulates lipid storage [61]. 
Adiponectin and leptin are hormones released from adipocytes that regulate glucose 
metabolism, and food intake, respectively [62]. Although important, these are just some of 
the features of adipogenesis. There are several elements that contribute to adipogenesis, 
including other transcription factors and cofactors, and signaling cascades.    
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Hypothesis  
We hypothesize that dual inhibition of ACC antagonizes expression of PPAR and 
transcriptional activation of its downstream targets resulting in inhibition of adipocyte 
differentiation. 
This hypothesis was tested in the preadipocyte line, 3T3-L1 with the dual ACC1 and ACC2 
inhibitor, Soraphen A and had the following objectives: 
1. To determine the extent to which ACC inhibition by SA alters adipogenic gene 
expression and lipid accumulation in 3T3-L1 cells. 
2. To determine the extent to which fatty acid oxidation plays a role in differentiating 
adipocytes.  
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Abstract  
Holocarboxylase synthetase (HLCS) catalyzes the covalent attachment of biotin to 
cytoplasmic and mitochondrial carboxylases, nuclear histones, and over a hundred human 
proteins. Nonhydrolyzable ketophosphonate (β-ketoP) and hydroxyphosphonate (β-
hydroxyP) analogs of biotin-5-AMP inhibit holocarboxylase synthetase (HLCS) with IC50 
values of 39.7 µM and 203.7 µM. By comparison, an IC50 value of 7 µM was observed 
with the previously reported biotinol-5ʹ-AMP.  The Ki values, 2.0 μM and 10.4 µM, 
respectively, are consistent with the IC50 results, and close to the Ki obtained for biotinol-
5ʹ-AMP (7 µM). The β-ketoP and β-hydroxyP molecules are competitive inhibitors of 
HLCS while biotinol-5ʹ-AMP inhibited HLCS by a mixed mechanism.   
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Introduction 
Holocarboxylase synthetase (HLCS) is the sole enzyme in the human proteome capable 
of catalyzing the covalent attachment of biotin to lysine residues.
1
 HLCS localizes in the 
cytoplasm, mitochondria, and cell nuclei.
1,2
 HLCS catalyzes biotinylation of five 
carboxylases in mitochondria and cytoplasm, which play key roles in gluconeogenesis, 
fatty acid metabolism, and leucine metabolism.
3
 In addition, a recent mass spectrometry 
screen identified 108 novel biotinylated proteins; heat shock proteins and enzymes from 
glycolysis are overrepresented among these proteins.
4
 HLCS orchestrates the assembly of a 
multiprotein gene repression complex in human chromatin, partially mediated through 
HLCS-dependent methylation of the histone methyltransferase EHMT1 and the nuclear 
receptor co-repressor N-CoR.
5
 Consistent with the importance of HLCS in intermediary 
metabolism and cell function, no living HLCS null person has ever been reported, and 
persons with HLCS mutations require lifelong treatment with pharmacological doses of 
biotin.
6 
HLCS-dependent biotinylation involves basically two steps (Fig. 1). In the first, 
activation of biotin by ATP generates the mixed anhydride biotin-5′-adenosine 
monophosphate (Bio-5′-AMP) (1). In the second step, the phosphate anhydride serves as an 
acylating agent for a target lysine in carboxylases (2), histones (3), and other proteins,
3,4,7 
covalently linking biotin to the substrate via an amide bond.  
The objective of this study was to develop a new class of synthetic HLCS inhibitors which 
could potentially be targeted to distinct cellular structures. Such an inhibitor would be a 
useful analytical tool in studies of HLCS-dependent biotinylation events in the cytoplasm, 
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mitochondria, and nucleus.  We based these studies on analogs of biotin-5-AMP, namely 
biotin β-ketophosphonate-5-AMP (β-ketoP) and biotin β-hydroxyphosphonate-5-AMP (β-
hydroxyP), that substitute a hydrolytically stable phosphonate for the acyl phosphate found 
in biotin-5-AMP (Figure 2a). The use of phosphonates as unreactive isosteres of 
phosphates is well established.
8 
For example, nonhydrolyzable aminoacyl analogs of 
aspartyl adenylate exhibit potent inhibitory activity against E. coli aspartyl-tRNA 
synthetase.
9 
  There is precedence for the efficacy of structurally analogous compounds 
sulfamides, sulfonamides, and 1,2,3-triazoles in the inhibition of a microbial biotin protein 
ligase, the HLCS ortholog BirA (Fig. 2b).
10-13  
We also investigated biotinol-5-AMP, a 
known phosphate analog of biotin-5-AMP which replaces the carbonyl oxygen with a 
methylene (CH2).
 10,14 
Materials and Methods 
Inhibitor synthesis (This work was done by W. Sittiwong; I have included it as part of 
the manuscript). 
The central element of the synthesis is the formation of a protected version of a biotin 
ketophosphonate (4a) via condensation of a biotin derived ketophosphonic acid (3) with a 
protected adenosine (Scheme 1). The synthesis begins with biotin methyl ester (1), 
prepared via the acid-catalyzed esterification of biotin.15 Reaction with the carbanion 
derived from methyl phosphonate was anticipated to offer a convenient route to a precursor 
of the desired phosphonates. However, reaction of ester 1 with the lithiated 
methylphosphonate, generated using lithium bis(trimethylsilyl)amide (LiHMDS) or n-butyl 
lithium (n-BuLi), 100 resulted in poor yields. Fortunately, reaction of the ester with a large 
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excess of the lithiated phosphonate, followed by quenching with deionized water to 
minimize demethylation of the phosphonate diester product, produced a 69% yield of 
dimethyl b-ketophosphonate 2.
16
 Selective monodemethylation with lithium bromide 
provides a good yield of mono ester 3. The pyridinium salt of 3 underwent coupling with 
20,30 isopropylidineadenosine (i-PrA) in the presence of O-(benzotriazol-1-yl)-N,N,N0 
,N0-tetramethyluronium hexafluorophosphate (HBTU) to provide a mixed phosphonate 
diester (4a) in 79% yield for two steps.
17,18
 110 No coupling was observed if N,N0-
dicyclohexylcarbodiimide (DCC) was substituted for HBTU. The acidic methylene of the 
ketone phosphonate was observed (NMR) to readily undergo H/D exchange upon 
dissolution in d4-MeOH. 
Reduction of the ketone with NaBH4 resulted in formation of the corresponding alcohol 
(4b) as a mixture of diastereomers at the newly formed stereocenter. Stirring the ketone 
diester (4a) or the alcohol diester (4b) in pyridine/water resulted in selective demethylation 
to afford monoesters 5a or 5b, respectively. Removal of the acetonide protecting group 
from the sugar followed by neutralization with ammonium bicarbonate provided the target 
120 biotin b-ketophosphonate (b-ketoP) 6a in 58% yield for two steps. The same 
procedure, when applied to alcohol 5b, furnished biotin-b-hydroxyphosphonate (b-
hydroxyP) 6b in 99% yield. 
 
Results 
Inhibition of HLCS: Biotin β-ketophosphonate-5-AMP (β -ketoP, 6a) inhibited HLCS in 
a dose-dependent manner. The polypeptide p67 is a substrate for biotinylation by HLCS. 
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When recombinant p67 was incubated with recombinant HLCS and 20 µM biotin in the 
presence of 50 to 500 µM β-ketoBP, HLCS inhibition was maximal at the highest inhibitor 
concentration tested. For example, the inhibition at 500 M β-ketoBP was 81.3±11.1% 
(P<0.01; n=4) compared with vehicle control (Fig. 3A). Data are presented as mean ± SD 
of 4 replicates. Incubation of p67 in the absence of HLCS produced no detectable signal 
(lane 6 in Fig. 3B). Under the conditions used here, IC50 and Ki for β-ketoBP equaled 
39.7±1.9 µM and 2.0 ±0.1 µM, respectively. When tested under identical conditions, β-
hydroxyP inhibited HLCS activity by 67.7 ±10.0% (P=0.0001; n=4) at concentrations of 
500 µM inhibitor.  The IC50 and Ki values calculated under these conditions were 203.7 
±3.7 µM and 10.4±0.2 µM, respectively.    β-KetoP is a competitive inhibitor of HLCS, 
based on competition studies with biotin. In these studies, the concentration of the inhibitor 
was held constant at 250 µM while that of biotin was varied from 0-320 µM; a second 
curve was generated in the absence of inhibitor (Fig. 3C). The apparent Vmax was similar 
for incubations with and without inhibitor [31.5±1.6 vs. 22.3±1.51 pmol biotinylated 
p67/(nmol HLCS x s); n=4] whereas the apparent Km for biotin was increased by the 
addition of inhibitor (77.9±10.3 vs. 1.6±1.8 µM biotin; n=4). β-HydroxyP (6b) also acts as 
a competitive inhibitor as evidenced by similar apparent Vmax values with and without 
inhibitor [20.6±1.8 vs. 22.6±1.4 pmol biotinylated p67/nmol HLCS x s); n=4] whereas 
reactions incubated with inhibitor increased the apparent Km for biotin (82.5±20.4 vs. 
1.9±1.8 µM biotin; n=4).   As a negative control we conducted incubations with a biotin 
ketophosphonic acid (compound 3 in Scheme 1). This substrate incorporates an 
electrophilic carbonyl carbon beta to a charged phosphonate but lacks the adenosyl 
34 
 
fragment hypothesized as essential for mediating HLCS inhibition. Consistent with this 
theory, the ketophosphonic acid compound did not inhibit HLCS (data not shown). 
The results were compared against assays conducted with biotinol-AMP, a known 
phosphate analog of biotin-5-AMP which has previously been employed for inhibition of 
BirA (biotin protein ligase).
10,11
 Biotinol-AMP reduces HLCS activity by 98.01±0.1% at 
concentrations of 500µM and has an IC50 value and Ki of 8.8±3.6 µM and 754 ± 303 nM, 
respectively. When reactions incubated with biotinol-AMP were challenged with 
increasing amounts of up to 320µM biotin, the apparent Vmax decreased compared to 
reactions without inhibitor (22.6 ± 1.4 vs. 5.9 ± 1.4 pmol biotinylated p67/(nmol HLCS x 
s); n=4)  and Km increased (1.9 ± 1.8 vs. 146 ± 79; n=4) indicating the biotinol-AMP most 
likely acts as a mixed inhibitor.     
Discussion  
There remains limited knowledge regarding the structure of HLCS and the mechanism of 
catalysis.
11,13b,20
 Similarly, little is known about the basis for selectivity between the classic 
carboxylase targets of HLCS and novel targets in chromatin and other proteins. The 
objective of this study was to develop a synthetic HLCS inhibitor capable of penetrating 
cell membranes and which could potentially be targeted to distinct cellular structures. Such 
an inhibitor would be a useful analytical tool in studies of carboxylase biotinylation in 
cytoplasm and mitochondria, studies of chromatin protein biotinylation and HLCS-
dependent formation of multiprotein gene repression complexes in nuclei, and studies of 
newly discovered species of biotinylated proteins throughout the cell.  
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Consistent with the importance of HLCS in intermediary metabolism and epigenetics, no 
living HLCS null individual has ever been reported, suggesting embryonic lethality. HLCS 
knockdown in Drosophila melanogaster (30% residual activity) produces phenotypes such 
as decreased life span and reduced heat resistance.
21
 Mutations and single nucleotide 
polymorphisms have been identified and characterized in the human HLCS gene; these 
mutations cause a substantial decrease in HLCS activity, aberrant gene regulation and 
metabolic abnormalities.
6,22
 Unless diagnosed and treated at an early stage, homozygous 
severe HLCS deficiency is characteristically fatal.
23
 Three independent cancer and patent 
databases correlate HLCS loss or mutation with an increase in detected tumors.
24
 
Several classes of biotin-50-AMP analogs have been applied to study the function of biotin 
protein ligases (BPLs), exemplified by HLCS as well as BirA, an enzyme catalyzing 
biotinylation of acyl carrier protein in prokaryotes.
10,13,14
 BirA from E. coli has 21% 
sequence similarity to HLCS.
25
 Biotinol-50-AMP, a phosphate ester lacking the acyl 
carbonyl of biotin-50-AMP, binds tightly to the Escherichia coli biotin repressor (KD = 1.5 
± 0.2 nM)11,20 and inhibits biotin transfer to the acceptor protein.
10,14
 Biotinol-50-AMP 
also binds tightly to Staphylococcus aureus BPL (Ki = 0.03 ± 0.01 lM). The activity of this 
analog would appear to suggest the key role of the phosphate moiety and the relative lack 
of importance of hydrogen-bonding interactions to the acyl carbonyl of biotin-50-AMP. 
However, other work has demonstrated that a sulfamoylcontaining bisubstrate analog, 
replacing the acyl phosphate with an acyl sulfonamide, strongly binds Mycobacteria 
tuberculosis BPL (MtBPL); a co-crystal revealing multiple hydrogen-bonding interactions 
between the protein and the acyl sulfonamide.
12
 More recently, a biotin-50-AMP analog 
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replacing the acyl phosphate witha 1,2,3-triazole was found to bind tightly to BPL and 
exhibit >1100-fold selectivity for the S. aureus BPL over the human homologue.13 This 
suggests the possibility of designing potent inhibitors of bacterial BPL. However, no 
similar approach has been used to studythe function of HLCS or human BPL. 
A model of the HLCS/biotin-50-AMP complex as well as the crystal structure of biotin-50-
AMP with BPL from Pyrococcus horikoshii OT3 (pdb:1wqw) suggests the importance of 
hydrogen bonding involving the carbonyl and phosphonate oxygen (Fig. S1).
13b,22b
 The b-
ketophosphonate and b-hydroxyphosphonate analogs introducedhere maintain the natural 
charge state of biotin-AMP and place a basic oxygen atom beta to the phosphonate group. 
However, in contrast to the BirA inhibitors described above, the ketophosphonate (b-ketoP, 
6) incorporates an electrophilic carbon at the location of the original acyl group in biotin-
50-AMP. Although the reduced activity of the new inhibitors compared with biotinol-AMP 
suggests that preservation of an electrophilic center (C=O) or hydrogen bonding group 
(CHOH) beta to phosphonate is of limited importance in inhibitor design, we note that 
the1,2,3-triazole analogs completely lacking a carbonyl group show no inhibition toward 
human BPL. It is also possible that conformational differences between the acyl phosphate 
of biotin-50-AMP and the phosphonate of 6a and 6b might also contribute to the reduced 
binding observed. 
In conclusion, we have described a new class of inhibitors of holocarboxylase synthetase 
HLCS based upon replacement of the ester of biotin-50-AMP with a ketone or a secondary 
alcohol. The analogs produce significant levels of inhibition with isolated enzyme. Efficacy 
of the new inhibitors in vivo has not been tested and further investigations are warranted.
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Fig 1. HLCS catalysis 
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Figure 2. (a) Chemical structure of biotin-5′-AMP and ketophosphonate ( 6a ) and 
hydroxyphosphonate ( 6b ) analogs; (b) reported sulfamoyl, sulfonamide, triazole, and 
phosphate inhibitors. 
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Scheme 1.  Synthesis of ketophosphonate (β-ketoP) and hydroxyphosphonate (β-
hydroxyP) analogs of biotin-5′-AMP   
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Figure 3. Inhibition of HLCS by biotin β-ketophosphonate-5′-AMP. (A) HLCS activity 
was quantified using infrared absorbance in the presence of 20 μM biotin and various 
concentrations of biotin β-ketophosphonate-5′-AMP (One way-ANOVA; ∗P<0.05; N = 4; 
Dunnett’s multiple t-test ∗p<0.05, ∗∗p<0.01, ∗∗∗p<0.001). (B) Representative gel, depicting 
biotinylation of p67 in the presence of various concentrations of biotin β-ketophosphonate-
5′-AMP. Lane 6 shows p67 incubated in the absence of HLCS. (C) Competitive inhibition 
of HLCS by biotin β-ketophosphonate-5′-AMP.
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Figure 4. Inhibition of HLCS by biotin β-hydroxyphosphonate-5′-AMP. (A) HLCS 
activity was quantified using infrared absorbance in the presence of 20 μM biotin and 
various concentrations of biotin β-hydroxyphosphonate-5′-AMP (One way-ANOVA; 
∗P<0.05; N = 4; Dunnett’s multiple t-test ∗p<0.05, ∗∗p<0.01, ∗∗∗p<0.001). (B) 
Representative gel, depicting biotinylation of p67 in the presence of various concentrations 
of biotin β-hydroxyphosphonate-5′-AMP. Lane 6 shows p67 incubated in the absence of 
HLCS. (C) Competitive inhibition of HLCS by biotin β-hyroxyphosphonate-5′-AMP. 
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Figure 5. Inhibition of HLCS by biotinol-5′-AMP. (A) HLCS activity was quantified 
using infrared absorbance in the presence of 20 μM biotin and various concentrations of 
biotinol-5′-AMP (One way-ANOVA; ∗P<0.05; N = 4; Dunnett’s multiple t-test ∗p<0.05, 
∗∗p<0.01, ∗∗∗p<0.001). (B) Representative gel, depicting biotinylation of p67 in the 
presence of various concentrations of biotinol-5′-AMP. Lane 6 shows p67 incubated in the 
absence of HLCS. (C) Competitive inhibition of HLCS by biotin β-hyroxyphosphonate-5′-
AMP. 
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Supplementary methods 
Expression and purification of HLCS 
 
ArcticExpress (DE3) Competent Cells (Agilent Technologies; Santa Clara, CA) 
transformed with HCS-pET41a(+) [Bao, Pestinger et al. 2011] were cultured in LB Broth 
Medium with 50 μg/ml of kanamycin and 20 μg/ml of gentamycin , and incubated 
overnight at 37°C. Bacteria were allowed to grow until an OD600 of 0.5- 1.0 was reached. 
Addition of isopropyl-beta-D-thiogalactopyranosid (IPTG) at a final concentration of 1mM 
induced protein expression and cells were incubated for an additional 24 hours at 12C. 
Cells were centrifuged at 4C (3,000 g for 30 minutes) and precipitated cells were 
resuspended in PBS with protease inhibitor cocktail (Sigma-Aldrich; St. Louis, MO). 
Samples were sonicated on ice (Branson 250 Digital Sonifier, Danbury, CT) three times for 
10-second burst alternating between 10-second resting periods on ice. The lysate were 
centrifuged at 10,000 g for 10 minutes at 4C. HCS fusion protein were purified by 
GSTrapTM FF Columns (GE Healthcare; Piscataway, NJ) on ÄKTAprotein purification 
system (GE Healthcare). HLCS in column fraction was identified by gel electrophoresis 
followed by coomassie blue staining. 
 
Expression and purification of p67 
 
The polypeptide p67 is frequently used to confirm biological activity of HCS. It is the C-
terminal 67 amino acid biotin carboxyl carrier (BCC) domain of the propionyl- CoA 
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carboxylase (PCC) α subunit (Leu637-Glu703). RosettaTM 2(DE3) Competent Cells 
(EMD Chemicals; Gibbstown, NJ) transformed with p67- pET30 [Kobza, Sarath et al. 
2008] were cultured in LB Broth containing 15 μl of kanamacyn, and incubated overnight 
at 37°C. Cells were grown until an OD600 of 0.5 - 0.6 was reached. p67 expression was 
induced by addition of 1mM IPTG and incubated for 16 hours at 37C. After incubation, 
samples were centrifugated at 3,000 g for 30 minutes and purified using His Trap FF 
Columns (GE Healthcare) on an ÄKTA protein purification system (GE Healthcare). 
Because BirA ligase in Escherichia coli is known to biotinylate some of the recombinant 
p67, the biotinylated fraction of p67 was removed using avidin columns.  
 
HLCS activity  
This assay is based on the HLCS dependent biotinylation of the p67 polypeptide. Briefly, 
recombinant biotin-free p67 and human HLCS and were prepared as described.
1
 The 
polypeptide p67 comprises the 67 C-terminal amino acids in PCC, including the biotin-
binding site K694; p67 is a well-established substrate for biotinylation by HLCS. Briefly, 
30 nM HLCS was incubated with 2 µM p67 in 75 mM Tris-acetate (pH 7.5), 45 mM 
MgCl2, 7.5 mM ATP, 0.3 mM DTT, and 20 µM biotin in the presence of 0.05 to 0.5 mM 
biotin β-ketoP, β-hydroxyP, or bio-5’-AMP (50 µl final volume) at 37ºC for 2 h; controls 
were incubated in the absence of inhibitor. Reactions were stopped by the addition of 50 µl 
of Tricine loading dye (Invitrogen) and heating at 95ºC for 10 min. Proteins were run on 
16% Tricine gels and transferred to polyvinylidene blots. Biotinylated p67 was probed 
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using anti-biotin and anti-goat conjugated secondary antibody, and was quantified using an 
Odyssey infrared imaging system. 
Competitive inhibition assays 
These experiments use a similar approach to HLCS activity assays with some 
modifications.  Briefly, 30 nM HLCS was incubated with 6 µM p67 and cofactors as 
described previously.  Reactions were incubated either in the presence or absence of 250 
µM inhibitor and challenged with increasing amounts of biotin ranging from 0-360 µM.  
Reactions were stopped by addition of 50 µl Tricine loading dye (Invitrogen) and heating 
at 95ºC for 10 min, and proteins were analyzed by Western blot analysis as described 
previously. Data presented in the paper reflects mean±SD of 4 replicates.   
IC50 and Ki Calculation  
The Michaelis-Menten constant (Km) and IC50 values were calculated using nonlinear 
regression analysis in Graph Pad Prism 6.0 software.  The Km was estimated by plotting 
substrate concentration vs. velocity obtained from enzyme activity and competition assays, 
and fitting the curve to the Michaelis-Menten equation.  The half-maximal inhibitory 
concentration (IC50) was calculated by plotting the logarithm of the concentration of 
substrate vs. binding and the curve generated was fit to the competition binding equation, 
One-site-Fit-logIC50 .  Ki was calculated from IC50 using an online-based tool.
2 
Statistics  
One-way ANOVA was used to determine whether differences among treatment groups 
were significantly different.  Dunnett’s multiple comparisons t-test was used to determine 
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if differences between the control and individual treatment groups were statistically 
significant. Statistical analysis was performed in Graph Pad Prism 6.0.  
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ABSTRACT 
 
Holocarboxylase synthetase (HLCS) is the sole protein-biotin ligase in the human 
proteome. HLCS has key regulatory functions in intermediary metabolism, including fatty 
acid metabolism, and in gene repression through epigenetic mechanisms. The objective of 
this study was to identify foodborne inhibitors of HLCS that alter HLCS-dependent 
pathways in metabolism and gene regulation. When libraries of extracts from natural 
products and chemically pure compounds were screened for HLCS inhibitor activity, 
resveratrol compounds in grape materials caused an HLCS inhibition of >98% in vitro.  
The potency of these compounds was piceatannol > resveratrol > piceid. Grape-borne 
compounds other than resveratrol metabolites also contributed toward HLCS inhibition, 
e.g., p-coumaric acid and cyanidin chloride. HLCS inhibitors had meaningful effects on 
body fat mass. When Drosophila melanogaster brummer mutants, which are genetically 
predisposed to storing excess amounts of lipids, were fed diets enriched with grape leaf 
extracts and piceid, body fat mass decreased by more than 30% in males and females. 
However, Drosophila responded to inhibitor treatment with an increase in the expression of 
HLCS, which elicited an increase in the abundance of biotinylated carboxylases in vivo. 
We conclude that mechanisms other than inhibition of HLCS cause body fat loss in flies. 
We propose that the primary candidate is the inhibition of the insulin receptor/Akt 
signaling pathway. 
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1. Introduction  
 
Holocarboxylase synthetase (HLCS) has essential functions in intermediary metabolism 
and gene regulation. The roles of HLCS in intermediary metabolism are mediated by five 
carboxylases, which attain biological activity through HLCS-dependent binding of the 
coenzyme biotin to distinct lysine residues in acetyl-CoA carboxylases (ACC) 1 and 2, 
pyruvate carboxylase (PC), propionyl-CoA carboxylase (PCC), and 3-methylcrotonyl-CoA 
carboxylase (MCC) [1]. All five carboxylases catalyze the covalent binding of bicarbonate 
to organic acids. ACC1 and ACC2 convert acetyl-CoA to malonyl-CoA in key steps in 
cytoplasmic fatty acid synthesis and the regulation of mitochondrial fatty acid uptake, 
respectively. PC converts pyruvate to oxaloacetate in gluconeogenesis in the cytoplasm. 
PCC converts propionyl-CoA to methylmalonyl-CoA in the metabolism of odd-chain fatty 
acids in cytoplasm. MCC converts 3-methylcrotonyl-CoA to 3-methylglutaconyl-CoA in 
leucine metabolism in cytoplasm. Recently, 108 new biotinylated protein were discovered 
by mass spectrometry analysis [2]. The biological function of their biotinylation is 
unknown, despite some evidence that biotinylation plays a role in the functionality of heat 
shock proteins [2,3]. 
Theoretically, inhibition of HLCS-dependent biotinylation of ACC1 and ACC2 might 
lead to a decrease in body fat. For example, preventing the biotinylation of ACC2 in the 
outer mitochondrial membrane would lead to decreased production of malonyl-CoA in the 
mitochondrial microdomain. Malonyl-CoA is a strong inhibitor of carnitine 
palmitoyltransferase 1, thereby decreasing the uptake and β-oxidation of fatty acids in 
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mitochondria [4]. Consistent with this observation, de-repression of carnitine 
palmitoyltransferase 1 by loss of ACC2 causes an increase in the β-oxidation of fatty acids. 
For example, energy expenditure and resistance to diabetes increase in ACC2 knockout 
mice compared with wild-type mice [5]. While these findings are controversial [6-8], a 
targeted inhibition of HLCS-dependent biotinylation of ACC2 in the outer mitochondrial 
microenvironment might prove to be a productive approach to improving metabolic health. 
Here, we tested the effects of a novel class of HLCS inhibitors, resveratrol metabolites, on 
carboxylase biotinylation and body fat mass in Drosophila melanogaster. Specifically, we 
sought to determine whether loss of carboxylase biotinylation is a more likely mechanism 
for decreasing body fat than the recently reported inhibition of insulin receptor-dependent 
insulin/Akt signaling pathway [9]. 
2. Materials and methods  
 
2.1. HLCS activity 
 
Two types of assays were employed to quantify HLCS activity. The basic principle is the 
same for both assays: Recombinant, full-length human HLCS (rHLCS) is prepared and 
purified as described [10]. rHLCS is incubated with biotin, cofactors, and the recombinant 
polypeptide p67, which comprises the 67 C-terminal amino acids in PCC, including the 
biotin-binding site K694 [11]. HLCS-dependent binding of biotin to p67 is assessed using 
streptavidin as probe. In the high-throughput variation of the assay, p67 is adsorbed to the 
plastic surface in 96-well plates for subsequent biotinylation by HLCS and quantification 
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using IRDye®-800CW-streptavidin and an Odyssey infrared imaging system (LI-COR, 
Lincoln, NE, USA). In the low-throughput variation of the assay, samples are incubated in 
a test tube, resolved by gel electrophoresis, and p67-bound biotin in transblots is probed 
with IRDye®-800CW-streptavidin and the Odyssey infrared imaging system. HLCS- or 
p67-free samples are used as negative controls in both assays. The gel-based assay has the 
advantage of convenient variation of assay parameters at the expense of comparably low 
throughput. 
 
2.2. HLCS inhibitors 
 
The PECKISH library of natural compounds was used for screening for HLCS inhibitors 
[12]. Briefly, the library contains aqueous extracts from >880 raw materials, including but 
not limited to fruits, spices, and leaf extracts disbursed in 96-well plates; plates and raw 
extracts were stored at -80°C. A subset of 72 extracts was used to screen for HLCS 
inhibitor activity. Grape leaves (Vitis vinifera, variety Gruner Veltliner) were obtained 
from Waldviertel’s Natureck (Plank am Kamp, Austria) and James Arthur Vineyards 
(varieties St. Croix and Edelweiss, Lincoln, NE). Extracts were prepared stirring 1 g of 
dried leafs into 10 mL of boiling distilled water and soaking the leaves for10 min. Red 
(Langers, Inc) and white grape juices (Best Choice, Inc.) and red and white table grapes 
were obtained at local food stores. Pomace are the solid remains from pressing grapes for 
juice. Fresh pomace was obtained from James Arthur Vineyards (variety Edelweiss) and 
extracted as described for grape leaves. Chemically pure gallic acid, quercetin, ferulic acid, 
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chlorogenic acid, ascorbic acid, phytic acid, caffeic acid, fumaric acid, 3-hydroxybenzoic 
acid, 4-hydroxybenzoic acid, catechin, cyanidin chloride, coenzyme Q10, 
hydroxyphenylethanol, ellagic acid, p-coumaric acid, citric acid, resveratrol, piceatannol 
and piceid were purchased from Sigma-Aldrich (St.Louis, MO, USA), Cayman Chemical 
(Ann Arbor, MI, USA) and Selleckchem (Houston, TX, USA) and used to prepare a second 
compound library with a focus on grape metabolites and for subsequent in-depth testing of 
individual compounds. For some compounds, the concentrations needed to cause a 50% 
inhibition of HLCS (IC50%) were estimated by testing serial dilutions of inhibitors and 
calculating IC50% through non-linear regression with the Graphpad Prism software 
(GraphPad Software, Inc., La Jolla,CA, USA). 
 
2.3. Identification of phenolics 
 
Separation and identification of major phenolics was accomplished with a Waters Millipore 
HPLC system (W.R. Grace and Co., Albany, OR) using a Waters 600s Controller with a 
Vydac reverse phase C18 column (Millford, MA, USA) as described previously [13] with 
some modifications. Separation was achieved with a gradient mobile phase of (A) 50 mM 
(NH4)H2PO4 at pH 2.6, (B) acetonitrile and 50 mM (NH4)H2PO4 pH 2.6 at 80:20 (v:v) and 
(C) 200 mM H3PO4, pH 1.5  with 100% A for 4 minutes, 92% A and 8% B for 6 minutes, 
14% B and 86% C for 12.5 minutes, 16.5% B and 83.5% C for 5 minutes, 25% B and 75% 
C for 22.5 minutes, 80% B and 20% C for 5 minutes, and 100% A for 5 minutes all at a 
flow rate of 1 ml per minute. Detection was performed using a Waters 2996 Photodiode 
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array detector scanning at 280 nm, 320 nm and 380 nm. Extracts of the grape leaves were 
passed through a 0.45 μm filter and were kept at 4°C before injection at 10 μl with a 
Waters 717Plus Autosampler. Sample areas were compared to a standard curve prepared 
from select phenols ranging from 50 μM to 6.25 μM. 
 
2.4. Body fat percentage in Drosophila melanogaster brummer mutants 
 
The brummer (bmm) gene encodes the lipid storage droplet-associated triacylglycerol 
lipase Brummer in Drosophila melanogaster, a homolog of mammalian adipose 
triglyceride lipase [14]. Loss of Brummer impairs the mobilizations from fat bodies in flies, 
i.e., brummer mutants are characterized by a large body fat mass [14]. Brummer mutants 
15828 and 15959 were obtained from the Vienna Stock collection (Vienna, Austria) and 
reared on instant fly food (Formula 4-24 Plain, Carolina, Inc.; Burlington, NC, USA). The 
flies can live a maximum of 90 days with an average lifespan of 45 days. Seven days after 
eclosure, male and female virgins were separated and fed diets containing 0.05% or 1% (by 
weight) grape leaf extracts (Gruner Veltliner) or piceid (0.012 or 0.12 μmol/L) for 21 days. 
Soraphen A is an inhibitor of ACC1 and ACC2 [15] and was used as a positive control (5 
μmol/L, 21 days). Flies were frozen (-80°C) and homogenized in a 5% Tween 20 solution. 
Triacylglycerols in the heat-inactivated (5 min at 70°C) extracts were incubated with 
Infinity Triglycerides solution (Thermo Scentific) at 37°C for 35 min and quantified 
colorimetrically (540 nm) using triolein as standard [16].  Biotinylated carboxylases were 
59 
 
isolated from fly homogenates as described previously [17] and analyzed by streptavidin 
blot analysis.   
 
 2.5. Statistics 
 
Bartlett’s test was used to confirm that variances were homogenous. One-way ANOVA 
and Fisher’s Protected Least Significant Difference was used to determine whether 
differences among treatment groups were significantly different. The unpaired t-test was 
used for pairwise comparisons. Statview 4.5 was used for all calculations [18]. P < 0.05 
was considered statistically different. Data are reported as means ± SD. 
3. Results 
 
3.1. HLCS inhibitors 
 
When the PECKISH library was screened for HLCS inhibitor activity using the 96-well 
plate assay, 21 extracts inhibited HLCS to an activity of <2% compared with inhibitor-free 
controls (see Fig. 1 for a representative image), including grape leaf extracts. The pool of 
candidate inhibitors was narrowed down as follows. First, extracts that caused a shift in the 
assay pH were disregarded. Representative examples include extracts from oranges and 
maté leaves (Ilex paraguariensis). Second, compounds that do not play a quantitatively 
meaningful role in diets were disregarded. Representative examples include Cassia fistula 
and Syzygium cumini. Grape leaf extract passed these screening steps and was further 
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investigated, partially because of the links of grape compounds such as resveratrol and its 
metabolites to cancer prevention, adipocyte differentiation, inhibition of inflammatory 
processes, and  low body fat mass [9,19-24]. 
The effects of grape leaf extract on HLCS activity were confirmed in independent 
experiments. First, raw material from the PECKISH library was re-extracted and analyzed 
using the gel-based assay. When aqueous extracts from 1 mg of grape leafs (in 10 µL) were 
incubated with HLCS (50 µL final volume), biotinylation of p67 was considerably lower 
compared with inhibitor-free sample (Fig. 2A); an HLCS-free sample was used as negative 
control and produced no signal. Effects of mate leaf extract, oranges extracts, and a 
synthetic HLCS inhibitor are shown for completeness. Second, new raw material was 
obtained from Waldviertel’s Natureck Inc., extracted, and analyzed for inhibitor activity. 
The results were essentially the same as for previous assays (not shown). Third, leaf 
extracts were prepared from local varieties of grapes (St. Croix and Edelweiss). These 
extracts also were potent inhibitors of HLCS although their activities were less than that of 
extracts from Gruner Veltliner (Fig. 2B). Fourth, grape juices and extracts from crushed 
table grapes were tested for inhibitor activity. Juices and white grapes inhibited HLCS to a 
meaningful extent (Fig. 2C,D); crushed red grapes also were effective inhibitors of HLCS 
but, at the highest concentrations tested, these effects might have been caused by shifts in 
the assay pH (not shown). Fifth, HLCS inhibitor activity was also detected in pomace (Fig. 
2E). 
Resveratrol and its metabolites piceatannol and piceid account for the inhibition of 
HLCS by grape materials, but other compounds in grapes also contribute toward HLCS 
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inhibition. When 19 compounds in grapes were assessed regarding their HLCS inhibitor 
activity by using the gel-based assay, 8 compounds inhibited HLCS by more than 90%, 
including the three resveratrol derivatives that were tested (Table 1). Piceatannol had a 
stronger effect on HLCS than resveratrol, which had a stronger effect than piceid, judged 
by dose-response studies comparing the three compounds (Fig. 3). IC50% values were 
0.28±2.12 µmol/L units for piceatannol, 3.70±0.0085 µmol/L units for resveratrol, and 
21.30±0.014 µmol/L units for piceid. Note that grape compounds other than resveratrol and 
its metabolites also inhibited HLCS. For example, p-coumaric acid and cyanidin chloride 
had an effect similar to that of resveratrol (Table 1).The concentrations of resveratrol and 
other polyphenols varied between grape varieties (Table 2). 
 
3.2. Body fat in Drosophila melanogaster brummer mutants 
 
Grape leaf extracts and chemically pure piceid caused a significant loss of body fat in 
brummer mutants flies. When flies were fed diets containing an aqueous extract equaling 
0.05 and 1% dried grape leaves for 21 days, the body fat mass was about 50% lower in 
males and females compared with controls (Fig. 4A-D). The same pattern was observed for 
brummer mutants 15828 (panels A and B) and 15959 (panels C and D). Likewise, when 
flies were fed diets containing 0.012 or 0.12 μmol/L piceid for 21 days, the body fat mass 
was about 30% lower in males and females compared with controls (Fig. 5A, B). Soraphen 
A, an inhibitor of ACC1 and ACC2, was used as positive control and caused a more than 
60% decrease in body fat (Fig. 5C, D). 
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3.3. Biotinylation of carboxylases in Drosophila melongaster brummer mutants 
 
Grape leaf extracts increased the amount of biotinylated carboxylases in brummer mutant 
flies. When flies were fed diets containing 1% dried grape leaves there was an increase in 
biotinylated ACC, MCC, PCC, and PC in males and an increase in biointylated PC in 
females.  The absence of detectable ACC1, ACC2, MCC, and PCC was previously 
reported in female flies [17]. This was accompanied by an increase in HLCS protein (Fig. 
6).  
4. Discussion 
 
This is the first report to identify naturally occurring inhibitors of HLCS. Our discoveries 
are relevant for human nutrition for two reasons. First, red and white grapes contain about 
5 mg/L and 0.6 mg/L, respectively, of total resveratrol, piceid, and piceatannol [25-27]. 
The comparably low HLCS inhibitor activity of piceid compared with piceatannol and 
resveratrol is partially offset by its high levels in grape-borne materials [25]. Second, table 
grapes and grape juice are consumed in fairly large quantities in the United States and other 
countries. For example, the annual per person consumption of grapes (white and red) was 
8.6 pounds in 2008 in the U.S., in addition to 5.7 pounds consumed in the form of grape 
juice [28]. Inhibitor activity was detected in all grape-based materials that were tested. 
Importantly, our studies provide unambiguous evidence that resveratrol and its metabolites 
inhibit HLCS not only in vitro but also cause body fat loss in Drosophila feeding studies. 
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While resveratrol metabolites inhibited HLCS efficiently in vitro, these effects were 
not seen in Drosophila feeding experiments in vivo.  In fact, we found that there was an 
increase in biotinylated carboxylases in male and female flies fed diets containing 20% 
grape leaf extracts.  This is due to an increase in HLCS expression.  Interestingly, a similar 
pattern was observed when HEK-293 cells were treated with either piceatannol or grape 
leaf extract, or the synthetic HLCS inhibitor, β-ketophosphonate-5’-AMP (Online 
Supplementary Figs 1 and 2).  Likewise, treatment of NIH/3T3 cells with the synthetic 
HLCS inhibitors β-hydroxyphosphonate-5’-AMP and biotin-5’-AMP [29] resulted in an 
increase in biotinylated carboxylases (Online Supplementary Fig. 3). We propose that 
HLCS is essential for cell survival and that cells and organisms respond to any perturbation 
of HLCS activity with an increase in HLCS expression. This proposal is based on the 
following rationale. The importance of HLCS is apparent in that no HLCS null individual 
has ever been reported, suggesting embryonic lethality, and mutations in the human HLCS 
gene cause a substantial decrease in HLCS activity and metabolic abnormalities [30,31].  
Additionally, HLCS knockdowon (~30% residual activity) in Drosophila melanogaster 
results in a reduced life span and heat tolerance [32] and aberrant gene regulation in human 
cell lines [33,34].  
When considering that resveratrol metabolites do not appear to inhibit HLCS activity 
in vivo, the decrease in body fat mass in Drosophila observed in this study likely is due to 
the mechanism proposed by Kwon et al. [9]. They propose that piceatannol inhibits 
differentiation of 3T3-L1 cells by delaying mitotic clonal expansion and in parallel 
preventing phosphorylation of the insulin receptor/Akt signaling pathway, leading to its 
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inhibition. The substantial decrease in body fat mass in Drosophila fed a diet supplemented 
with grape leaf extract and piceid illustrates the potential benefits of these compounds for 
human health, considering the current epidemic of obesity and obesity-related diseases [35-
37].  
A few key observations in this study are worthwhile pointing out. First, no apparent 
difference was noted when comparing materials from red and white grapes. Second, the 
variety of grapes might be important regarding HLCS inhibitor activity, e.g., leaf extracts 
from Gruner Veltliner were more effective than extracts from Edelweiss. Third, bioactive 
compounds other than resveratrol and its metabolites, also contribute toward HLCS 
inhibitor activity in grape materials, e.g., p-coumaric acid and cyanidin chloride. Therefore, 
synergisms need to be considered in future studies, and experiments with chemically pure 
compounds should always be supplemented with studies using crude materials. Fourth, 
pomace contains meaningful amounts of HLCS inhibitors. It might be worthwhile 
considering purifying these compounds from pomace, which is typically considered as 
waste product in the production of wine and grape juice. 
The following uncertainties remain. First, it is unknown whether HLCS inhibitors also 
affect gene repression through HLCS-dependent epigenetic mechanisms. We abstained 
from conducting such studies because effects of HLCS in gene repression are caused by 
HLCS/protein interactions that might not depend on the catalytic activity of HLCS [38-40]. 
Second, it is unknown which of the four domains in the HLCS domain interact with 
resveratrol and its metabolites [41]. Considering that the comparatively bulky glucose 
residue in piceid impaired inhibitor activity compared with resveratrol, one could assume 
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that the resveratrol binding site in HLCS is rather specific [25]. We also do not know 
whether effects of resveratrol compounds are stereospecific; trans isomers or piceid and 
resveratrol are more abundant than cis isomers in grape materials [25]. Third, he expression 
of HLCS is regulated by three promoters [42,43], but the responsiveness of regulatory 
elements in these promoters to HLCS inhibitors is unknown. These uncertainties are 
currently being addressed in our laboratories. 
Taken together, resveratrol metabolites caused a substantial 50% fat loss in flies. Our 
studies suggest that loss of biotinylation events do not contribute to loss of body fat, and 
that the observed effects can be attributed to inhibition of the insulin receptor/Akt signaling 
pathway as proposed previously [9]. 
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Table 1. Inhibition of HLCS by bioactive compounds in grapes. 
Compound
1
 Inhibitor activity² 
Piceatannol +++++ 
Resveratrol +++++ 
Piceid +++++ 
p-Coumaric acid +++++ 
Quercetin +++++ 
Cyanidin chlorid +++++ 
Gallic acid +++++ 
3-Hydroxybenzoic acid +++++ 
Ellagic acid ++++ 
Chlorogenic acid ++++ 
4-Hydroxybenzoic acid ++++ 
Fumaric acid +++ 
Citric acid +++ 
Ascorbic acid +++ 
Ferulic acid +++ 
Caffeic acid +++ 
Phytic acid ++ 
Hydroxyphenylethanol + 
Coenzym Q10 + 
1
Sorted by effect size. 
2
Symbols denote inhibitor activity (+++++, >90% inhibition of HLCS; ++++, >80% inhibition; 
+++, >60% inhibition; ++, >40% inhibition; +, <20% inhibition), judged by HLCS-dependent 
biotinylation of p67 in the gel-based HLCS assay and gel densitometry. Compounds were tested 
at concentrations of 0.05 to 5.7 mM. 
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Table 2. Concentrations of polyphenols in grape leaves in two varieties.
1
 
Compound Gruner Veltliner Edelweiss 
 µmol/kg 
Piceatannol  n.d.
2
 0.66±0.25 
Resveratrol  n.d. 0.64±0.68 
Piceid  3.07±0.11 1.74±0.44 
Chlorogenic acid  8.42±0.39 0.92±0.30 
 
1
Values are means ± standard deviations. 
2
n.d., not detectable.  
69 
 
 
Fig. 1. Representative example of HLCS activity in samples treated with extracts from the 
PECKISH library of natural compounds. HLCS activity was assayed using a 96-well plate 
format, values in individual wells denote HLCS activity (% of controls). Identifiers: B3 and B4 = 
vehicle controls; C3 = grape leaf extract; A4 = Cassia fistula; C7 = Syzygium cumini; row H is 
the calibration curve containing defined amounts of HLCS. 
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Fig. 2. Effects of grape products on HLCS activity. (A) Gel-based assay of HLCS activity in the 
absence and presence of grape leaf extract. A sample without HLCS was used as negative 
control. Extracts from maté leaves and oranges were not considered for subsequent studies, 
because of their inhibitor activity was caused by shifts in the assay pH as discussed in the text. 
(B) Comparison of leaf extracts from Gruner Veltliner, St. Croix, and Edelweiss. HLCS activity 
was measured in the presence of and aqueous extract of 500 µg grape leaves in a sample volume 
of 50 µL; controls were prepared using vehicle and by omitting HLCS. Lanes were electronically 
re-arranged to facilitate comparisons. (C) Effects of grape juices on HLCS activity. (D) Effects 
of crushed white grapes on HLCS activity, quantified by gel densitometry. (E) Effects of pomace 
extract (variety Edelweiss) on HLCS activity.  
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Fig. 3. Comparison of the effects of resveratrol, piceatannol, and piceid on the inhibition of 
HLCS. 
  
72 
 
 
 
Fig. 4. Effect of grape leaf extract on body fat mass in male and female Drosophila 
melanogaster brummer mutants 15828 (panels A and B) and 15959 (panels C and D). Flies were 
fed a diet supplemented with 0.05 or 1% grape leaf solids (as extracts) for 21 days; controls were 
fed an extract-free diet. 
a,b
Bars not sharing the same letter are significantly different (P < 0.05; 
n=4 tubes, each containing 40 flies). 
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Fig. 5. Effect of piceid (panels A and B) and soraphen A (panels C and D) on body fat mass in 
male and female Drosophila melanogaster brummer mutant 15828. Flies were fed a diet 
supplemented with 0.012 μmol/L piceid, 0.12 μmol/L piceid, or 5 μmol/L soraphen A for 21 
days; controls were fed piceid-free and soraphen A-free diets. 
a,b
Bars not sharing the same letter 
are significantly different (P < 0.05; n=4 tubes, each containing 40 flies). 
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Fig. 6. Abundance of biotinylated holocaboxylases and HLCS in male and female Drosophila 
melanogaster brummer mutant 15828. Flies were fed a diet supplemented with 0.05 or 1% grape 
leaf solids (GLS, as extracts) for 21 days; controls were fed an extract-free diet. Biotinylated 
carboxylases, HLCS, and β-actin (control) were probed using streptavidin, anti-HLCS, and anti-
β-actin, respectively. ACC, acetyl-CoA carboxylases; MCC, 3-methylcrotonyl-CoA carboxylase; 
PC, pyruvate carboxylase; PCC, propionyl-CoA carboxylase. 
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Figure 7. (Online Supplementary Fig. 1). Holocarboxylase profile of HEK293 cells treated 
with or without piceatannol or grape leaf extract. HEK293 cells were treated with either 50 μM 
piceatannol or 0.25% grape leaf solids for up to 8 days.  Cells were collected for analysis of 
holocarboxylase abundance.  Biotinylated carboxylases were probed with streptavidin. ACC, 
acetyl-CoA carboxylases; MCC, 3-methylcrotonyl-CoA carboxylase; PC, pyruvate carboxylase; 
PCC, propionyl-CoA carboxylase. 
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Figure 8. (Online Supplementary Fig. 2). Holocarboxylase profile of HEK293 cells treated 
with with or without β-ketophosphonate-5’-AMP. HEK293 cells were incubated with 250 μM β-
ketophosphonate-5’-AMP for 6 days. Biotinylated carboxylases were probed with streptavidin. 
ACC, acetyl-CoA carboxylases; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MCC, 3-
methylcrotonyl-CoA carboxylase; PC, pyruvate carboxylase; PCC, propionyl-CoA carboxylase.  
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Figure 9. (Online Supplementary Fig. 3). Holocarboxylase profile of NIH3T3 cells treated 
with β-hydroxyphosphonate-5’-AMP, biotinol-5’-AMP or without inhibitor.  NIH3T3 cells were 
incubated with 250 μM β-hydroxyphosphonate-5’-AMP for 6 days. Biotinylated carboxylases 
were probed with streptavidin. ACC, acetyl-CoA carboxylases; MCC, 3-methylcrotonyl-CoA 
carboxylase; PC, pyruvate carboxylase; PCC, propionyl-CoA carboxylase.  
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Abstract 
Acetyl-CoA carboxylases (ACC) 1 and 2 catalyze the carboxylation of acetyl-CoA to malonyl-
CoA and depend on biotin as a coenzyme. Malonyl-CoA produced by cytoplasmic ACC1 is a 
precursor in fatty acid (FA) synthesis. Malonyl-CoA produced by ACC2 in the outer 
mitochondrial membrane is an inhibitor of FA import into mitochondria for subsequent 
oxidation. We hypothesized that ACCs are checkpoints in adipocyte differentiation and tested 
this hypothesis using the ACC1 and ACC2 inhibitor soraphen A in murine 3T3-L1 
preadipocytes. Treatment of 3T3-L1 cells with as little as 100 nM of the microbial ACC inhibitor 
soraphen A (SA) inhibited lipid droplet accumulation and was accompanied by a 29% and 11% 
decrease in the expression of PPARγ mRNA and FABP4 mRNA, respectively, as markers of 
adipocyte differentiation four days after treatment. Treatment of 3T3-L1 cells with 200 μM 
palmitate partially restored lipid accumulation and fully rescued PPARγ and FABP4 mRNA 
expression. This observation suggests that loss of ACC1-dependent FA synthesis might account 
for some of the effects of SA in lipid accumulation and adipocyte differentiation. We propose 
that loss of ACC2 also contributed to this phenomenon, based on our observation that treatment 
with 100nM SA caused a 300% higher rate of fatty acid oxidation compared with solvent 
controls. Glucose uptake is maintained in these cells despite decreased GLUT4 mRNA 
expression upon treatment with SA. SA did not alter lipid accumulation if treatment was initiated 
on day eight after induction of differentiation. We conclude that inhibition of ACC 1 and 2 alter 
lipid metabolism but not adipogenesis in 3T3-L1 cells.  
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Introduction 
Acetyl-CoA carboxylase 1 and 2 (ACC 1 and 2) depend on biotin as a covalent bound coenzyme 
and catalyze the synthesis of malonyl-CoA through the carboxylation of acetyl-CoA. Malonyl-
CoA synthesized from cytoplasmic ACC1 and mitochondrial membrane associated-ACC2 serves 
as the C2 donor in fatty acid synthesis and as a regulator of beta-oxidation of long chain fatty 
acids, respectively [1,2]. Malonyl-CoA produced from ACC2 is a potent inhibitor of carnitine 
palmitoyltransferase I (CPTI), the enzyme responsible for catalyzing the transfer of an acyl 
group from coenzyme A to carnitine[3]; the binding of carnitine to fatty acids is the rate-limiting 
step in mitochondrial fatty acid import for subsequent beta-oxidation[4]. 
Due to their key roles in fatty acid metabolism and intracellular lipid accumulation, ACCs have 
attracted considerable attention as potential targets for lipid lowering treatments. For example, 
whole body mutant ACC2-/- mice fed a high fat diet or high fat/high-carbohydrate diet for 4 
months had lower body weights than their wild type cohorts. Additionally, increased glucose 
uptake and insulin sensitivity was displayed by the mutant mice demonstrating their protection 
from diabetes and this was accompanied by a decrease in triglyceride content in the liver and 
skeletal muscle in ACC2-/- mutant mice [5-7]. However, these findings are highly controversial.  
Other studies found no differences in overall energy balance between skeletal muscle-specific 
and global ACC2 knockout (ACC2KO) mice [8,9]. Body weights and food intake were similar in 
ACC2KO and wild-type controls [8,9] and this was accompanied by a decrease in malonyl-CoA 
levels and increased fatty acid oxidation in skeletal muscle.  The increase in fatty acid oxidation 
can be attributed to inhibition of ACC2, which leads to a de-repression of CPTI, thereby 
increasing beta-oxidation.  
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Mice lacking ACC1 are embryonically lethal [10] and two liver specific knockouts of ACC1 
(LACC1-/-) generated by Kusunoki’s and Wakil’s groups [11,12] show conflicting results. There 
were no differences in fatty acid synthesis of malonyl-CoA levels in Kusonoki’s LACC1-/- mice 
liver samples compared to WT mice while liver samples from Wakil’s LACC1-/- produced the 
opposite effects [11,12].  
The inconsistent results between ACC1 and 2 knockout mice suggest that inhibition of both 
enzymes may be required to alter energy balance. Soraphen A (SA), originally isolated from the 
myxobacterium Sorangium cellulosum, is a macrocylic polyketide that displays antifungal 
activity. Genetic and biochemical studies indicate that eukaryotic ACC are inhibited by SA at 
concentrations [13,14]  as low as 1 nM [15]. Structural studies demonstrate that the compound 
acts by binding to the biotin carboxylase domain of the ACC enzymes preventing dimerization of 
eukaryotic ACCs [15]. Male C57Bl/6 mice fed a high fat diet supplemented with SA had reduced 
weight gain, adipose tissue and fasting plasma insulin levels as compared to mice fed high fat 
diets without SA supplementation and these levels were comparable to those of the control [16]. 
One possible mechanism for the observed reduction in fat mass displayed by mice fed a high fat 
diet supplemented with SA is a reduction in adipocyte differentiation. 
Lodhi et al. reported that fat-specific knockout of fatty acid synthase (FASKOF) in mice 
lessened diet-induced obesity and increased brown fat-like cells in these mice.  PPARγ protein 
expression was unaffected in adipose tissue of FASKOF mice but protein expression of the 
PPARγ target aP2 (also known as FABP4) was decreased.  Gene expression of PPARγ targets 
including aP2,  lipoprotein lipase, fatty acid translocase (CD36), and CCAAT/enhancer binding 
protein alpha (C/EBPα) were also decreased in FASKOF mouse adipose tissue. Fatty acid 
synthase knockdown in 3T3-L1 cells led to a decrease in aP2 and CD36 protein expression [17]. 
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We propose that inhibition of ACC1 and 2 by Soraphen A will prevent production of malonyl-
CoA which feeds into the fatty acid biosynthesis pathways and prevents the production of 
endogenous ligands for PPARγ activation and adipogenesis.   
Materials and Methods 
Cell lines and cell culture 
Mouse preadipocyte 3T3-L1 cells were purchased from American Type Culture Collection (Cat 
no. CL-173). Cells were seeded at a density of 1.5 x 10
5 
in 12 well plates or 5 x 10
5 
in T25 flasks 
and maintained at 37C in a 5% CO2/95% air atmosphere. 3T3-L1 preadipocytes were 
maintained in DMEM containing 25 mM glucose and 10% bovine calf serum (BCS) until 2 days 
after becoming confluent (designated as day 0) when media was switched to DMEM , 25 mM 
glucose, 10% fetal bovine serum (FBS), and one of the following differentiation cocktails: 
cocktail 1 produced final concentrations of 1.75 M insulin, 1 μM dexamethasone, and 500 μM 
3-isobutyl-1-methylxanthine (IBMX), and cells were treated with the cocktail for 2 days; 
cultures were continued for another two days in media supplemented with 1.75 M insulin, but 
no dexamethasone and no 3-isobutyl-1-methylxanthine. Cocktail 2 produced final concentrations 
of 1 M rosiglitazone and 1.75 M insulin and was given to cells for 4 days when media was 
switched to DMEM/high glucose and 10% FBS without rosiglitazone and insulin. Where 
indicated, SA was added to cells at a concentration of 100 nM or 1 M. SA was a gift from Dr. 
Rolf Jansen of the Helmholtz-Centre for Infection research in Braunschwig, German. Cell 
viability was determined using trypan blue exclusion [18].  
RNA isolation and quantitative real-time PCR (RT-qPCR) 
Total RNA was isolated using illustra RNA spin Mini RNA isolation kit (GE healthcare) and the 
ImProm-II reverse transcription system (Promega) was used to synthesize cDNAs. Relative 
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mRNA expression was quantified by RT-qPCR and the ΔCt protocol as described previously 
[19] using the primers in Table 1.  Assays were performed in triplicate and results were 
normalized to 18s ribosomal RNA.  
Fatty acid oxidation assay 
The rate of fatty acid oxidation was assessed by measuring the release of tritiated water from 
radiolabeled palmitate [20]. Briefly, [9,10-
3
H(N)]-palmitic acid (NEN Perkin Elmer) was mixed 
with unlabeled sodium palmitate (TCI America, Portland, OR); 20 mM  in 0.01 N NaOH to 
adjust the specific radioactivity to about 32 mCi/mmol. Palmitate was complexed to ultra fatty 
acid free bovine serum albumin (BSA, Roche, Basel, Switzerland) at a 3:1 molar ratio using 
stock solutions of 2 mM BSA and 20 mM Na-palmitate. Desired quantity of radiolabled 
palmitate was added to 20mM palmitate prior to conjugation to BSA.  
Cell differentiation was induced as described above. At 6 days post-differentiation, media was 
changed to MEM containing 2% FBS for 12 hours. Cells were treated with either 100 nM SA 
beginning at day 0 or 1 M SA 12 hours prior to addition of radiolabeled fatty acids or with 
solvent (control). Etomoxir (Tocris Biosciences, Minneapolis, MN) inhibits fatty acid oxidation 
[21] and was added to cell cultures one hour prior to addition of palmitate (positive control).  
After 12 hours, media was replaced with serum free media and cells were incubated with 
radiolabeled palmitate at about 0.5 Ci/well; background radioactivity was assessed by 
incubating cells in fatty acid-free BSA. Incubations were continued for two hours. Media were 
collected and the release of tritiated water was assessed as described previously [20] with the 
following modifications. Trichloroacetic acid was added to media to produce a final 
concentration of 10 % trichloracetic acid, and samples were allowed to precipitate for 30 minutes 
at 4C. Samples were centrifuged at 16000 g for 10 minutes at 4C and 250 L of supernatant 
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was transferred to new tubes containing 42 L of 6 N NaOH. Samples were applied to a 
DOWEX 1x2,200-400 mesh, ion-exchange resin (1 mL packed volume), which retains the 3H-
labeled water whereas [3H] palmitate elutes near the solvent front. Columns were washed with 
300 μL of ultrapure water and radioactive water was eluted with 2 mL ultrapure water for 
analysis in a liquid scintillation counter. Results were normalized to total protein concentration.       
Glucose uptake assays 
The rate of glucose uptake was assessed by measuring cellular uptake of the radiolabled glucose 
analog 2-deoxy-D-glucose [22]. Cell differentiation was induced as described above. At 6 days 
post-differentiation, media was changed to MEM containing 10% FBS and 5.5mM D-glucose for 
24 hours. Cells were treated with either 100 nM SA beginning at day 0, 1 M SA 12 hours prior 
to addition of radiolabeled glucose, or with no SA. On day 7, media was replaced with 1 mL of 
HBSS with treatments and with or without 100 nM insulin, for 10 minutes followed by addition 
of 20 L of HBSS containing 4 nmol 2-[1,2-3H(N)]deoxy-d-glucose [0.05 Ci/mL] for 90 min 
incubated at 37C. Uptake was terminated by the addition of ice-cold KRBC supplemented with 
25 mM D-glucose to remove background radioactivity. Cells were lysed using 300 µL 0.1% 
SDS-PBS and total cellular lysate was subjected to liquid scintillation counting to determine 
cellular uptake. Results were normalized to total protein concentration.   
Protein expression 
Cells were lysed directly in the culture dish using 0.5 mL RIPA buffer containing protease 
inhibitor cocktail. Cells were scraped off and lysate was transferred to a 1.5 mL tube where they 
were let stand for 5 minutes at 4C after which lysate was spun down at 14000g for 15 minutes at 
4C and supernatant was transferred to another tube. Total protein concentration was measured 
by BCA assay and 4g of protein was mixed with NuPage loading dye (Invitrogen) and heated 
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to 95C for 10 minutes. Proteins were run on 3-8% Tris-acetate gels and transferred to 
polyvinylidene blots. The expression of biotinylated ACC1 and 2 was assessed using streptavidin 
as a probe [23].         
Oil Red O (ORO) staining and lipid quantitation 
Cells were fixed with 4% paraformaldehyde and lipids were stained using ORO[24]. 
Hematoxylin, which binds to the nucleus was used as a counter stain. Microscopy images were 
obtained using a Nikon Ti-S Inverted Fluorescence Microscope. The relative accumulation of 
lipids was quantified by extracting ORO using 100% isopropanol and measuring the absorbance 
at 490 nm by a spectrophotometer.  
Statistics 
One-way ANOVA was used to determine whether differences among treatment groups were 
significantly different. Dunnett’s multiple comparisons t-test was used to determine if differences 
between the control and individual treatment groups were statistically significant. All data 
presented are means  standard deviation. Statistical analysis was performed using Graph Pad 
Prism 6.0.  
 
Results 
Inhibition of ACCs by SA impairs adipogenic gene expression and lipid accumulation 
We determined the effects of a SA dose response on lipid droplet accumulation in 3T3-L1 cells. 
3T3-L1 cells were treated with either 100 nM, and 1 M SA for 8 days and cells were fixed and 
stained with ORO. Concentrations as little as 100 nM SA resulted in a complete elimination of 
lipid droplets (Fig 1. A). Treatment did not affect cell viability (units = % viability): 88.6 ± 9.6 
% for solvent control, 88.6 ± 9.7 % for 100 nM SA, and 90.2 ± 4.8 % for 1000 SA (P>0.05, 
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n=3). Reductions in lipid accumulation were observed with SA concentrations of ~50 nM (data 
not shown). Subsequent experiments were performed with 100 nM and 1 M of SA. To 
understand the effects of ACC inhibition by SA on adipocyte differentiation, we looked at 
PPAR mRNA expression; PPAR is the master regulator of adipogenesis. Cells treated with 100 
nM or 1 M SA showed a dose-dependent decrease in PPAR mRNA expression at both days 4 
and 8 (Fig 1. B). Fatty acid binding protein 4 (FABP4 also known as aP2) transports fatty acids 
and lipophilic substances between the cytoplasm and nucleus and is a downstream target of 
PPAR. Its gene expression was downregulated in a dose-dependent manner similar to PPAR at 
days 4 and 8, although this was not significant (Fig 1. C).  
 
Palmitate partially restores lipid accumulation and PPAR expression in SA treated cells.  
Palmitate has previously been shown to activate PPAR in an vitro-ligand assay [25] and 
stimulate triacylglycerol accumulation and adipocyte differentiation in 3T3-L1 cells [26]. SA 
treatment caused a ~75% decrease in lipid accumulation compared with solvent controls, which 
was only partially restored by exogenous palmitate (Fig.2A). Importantly, exogenous palmitate 
restored the expression of the differentiation markers, PPAR mRNA and FABP4 mRNA to 
control levels in SA-treated cells (Fig. 2B, C).  Palmitate did not affect the viability of the cells. 
(data not shown).  
 
SA treatment results in an increase in fatty acid oxidation 
ACC1 is highly abundant in adipose tissue and plays a prominent role in de novo lipogenesis.  
ACC2 expression is comparatively lower in adipose tissue and would not be expected to be 
affected by SA treatment. To measure fatty acid oxidation, cells were treated with [9,10-
3
H]-
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palmitic acid after pretreatment with DMSO, 100 nM SA starting from day 0, or 1 M SA for 12 
hours. When [9,10-
3
H]-palmitic acid undergoes dehydrogenation at the acyl-CoA dehydrogenase 
step, 
3
H-lableled H2O is released into the media and can be quantified. Cells treated with either 
100 nM SA for 7 days or 1 M SA for 12 hours had a ~3 fold and ~2 fold increase in fatty acid 
oxidation, respectively. Administration of BSA resulted in no change in fatty acid oxidation 
(FAO) between treatment groups. Etomoxir served as a negative control, inhibiting fatty acid 
oxidation by ~40% compared with controls (Fig. 3).  There was no change in ACC protein 
expression between the control and treatment groups (data not shown). 
 
Glucose uptake is maintained in SA treated cells 
Impaired triacylglycerol storage can lead to insulin resistance [27]. Lipid accumulation is 
attenuated in our SA-treated cells and we wanted to observe the effects of SA on the expression 
of glucose transporter 4 (GLUT4) and glucose uptake.  Treatment with 100nM SA was effective 
in reducing the amount of GLUT4 mRNA while the addition of palmitate rescued its expression 
(Fig. 4A). To determine if glucose uptake was affected upon treatment with SA treatment, 
cellular accumulation of glucose was measured using 2-[1,2-
3
H(N)]deoxy-D-glucose. Despite 
changes in GLUT4 mRNA expression, glucose uptake was unchanged even upon stimulation 
with insulin, indicating that insulin sensitivity is maintained in these cells. 
 
Continuous administration of SA is required to maintain an uncommitted phenotype  
To determine if SA could completely block differentiation, a series of time course experiments 
were performed to establish a time frame during which cells would remain undifferentiated even 
upon removal of SA. Cells were treated with SA for 8,10, or 12 days and collected at day 16. 
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PPAR and FABP4 mRNA expression was not significantly different between treatment groups 
when measured at day 16 (Fig.5 A,B).  Interestingly, PPARγ and FABP4 mRNA expression, 
although not significant, showed a trend to increase in SA treated cells, possibly as a way to 
overcome the lack of activaton. Consistent with the lack of changes in adipogenic gene 
expression between treatment groups, lipid began accumulating upon removal of SA (data not 
shown). SA administration in terminally differentiated adipocytes does not eliminate lipid 
droplet formation. 
Introduction of a dominant negative PPARγ into mature 3T3-L1 cells results in de-
differentiataion of adipocytes with decreased expression of adipocyte markers and lipid 
accumulation [28]. We wanted to determine if SA could revert the phenotype of terminally 
differentiated 3T3-L1 cells by downregulating the expression of PPAR and lipid accumulation.  
cells were differentiated for 8 days and subsequently treated with either 100 nM or 1 M SA for 
4 days. There was no change in the size or the amount of lipid droplets after 4 days of SA 
administration at either concentration when administration started at day 8 (Fig. 5B). These 
results indicate that continuous administration of SA beginning in early stages of differentiation 
is required to inhibit lipid accumulation in 3T3-L1 cells.  
Differentiation by rosiglitazone and insulin maintains adipogenic gene expression upon 
treatment with SA 
Rosiglitazone, a member of the thiazolidinediones, a class of drugs that is prescribed as Type 2 
diabetes medication, is an agonist of PPARγ that binds to the receptor with a Kd of 40 nM [29]. 
Cells were differentiated with rosiglitazone and insulin and treated with either 100 nM SA with 
or without 200 μM palmitate. Surprisingly, gene expression analysis at day 8, showed an 
increase in PPARγ and FABP4 expression when treated with both SA 100 nM or SA 100 nM 
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and 200 μM palmitate (Fig. 6A,B) compared with controls. Treatment with 200 M palmitate 
was particularly effective in elevating PPARγ and FABP4 mRNA expression. There were no 
significant differences in GLUT4 mRNA expression between treatment groups (Fig. 6C). 
Despite these changes in gene expression, the control cells had the most lipid accumulation(Fig. 
6D).  
 
Discussion 
Soraphen A is a naturally occurring compound derived from the soil dwelling myxobacterium 
Sorangium cellulosum. This polyketide is likely essential for its survival, protecting bacteria 
from pathogenic fungi [30]. The goal of this study was to determine if inhibition of ACCs by SA 
is capable of blocking adipocyte differentiation. The rationale for this study is based on the fact 
that malonyl-CoA produced from ACCs feeds into the fatty acid synthesis pathway that produces 
endogenous ligands for PPAR, thus promoting adipogenesis. Previously, mice fed a high fat 
diet supplemented with SA, were found to have reduced adiposity and weight gain [16]. The 
study did not provide a reason for the observed decrease in body fat but it may be due to the 
inhibition of adipogenesis. A fat-specific FAS knockout mouse model was shown to lead to an 
increase in brown fat-like adipocytes in subcuanteous adipose tissue and increased energy 
expenditure [17]. This is the first report to observe that SA decreases adipogenesic gene 
expression and by triacylglycerol accumulatio in 3T3-L1 cells.  Our findings that FABP4 is 
decreased in 3T3-L1 cells is consistent with the observation that in primary mouse embryonic 
fibroblasts, protein and gene expression of aP2 (FABP4) was decreased when there was FAS 
knockdown in these cells.  Additionally, 3T3-L1 cells with FAS knockdown, [17] also showed a 
decrease in aP2 and CD36 protein expression. However, we also saw a decrease in gene 
95 
 
expression of PPAR while Lodhi et al. reported no change in PPAR protein expression.  They 
attribute these changes to a lack of PPAR activation. Our finding that PPAR gene expression is 
decreased in SA-treated cells does agree with a previous report that found that an inhibitor of the 
CT domain in ACCs, choloracetylated biotin derivative (CABI), blocked adipogenesis as 
observed by inhibition of PPAR protein expression and a decrease in lipid accumulation [31]. 
However, CABI is less potent than SA at inhibiting lipid accumulation and adipogenic protein 
expression. Concentrations of 8 M of CABI were required to see a reduction in PPAR protein 
expression and lipid accumulation whereas 100 nM of SA was sufficient to block adipogenic 
gene expression and lipid accumulation. (Fig1A,C-D).   
Lipogenesis is favored upon insulin activation of ACC with the majority of de novo lipogenesis 
feeding into triglyceride accumulation [32]. Because lipid accumulation was completely 
eliminated in SA treated cells palmitate supplementation was administered to see if it could 
restore adipogenesis. Palmitate has previously been shown to stimulate triacylglycerol 
accumulation and adipocyte differentiation in 3T3-L1 cells [26] and activates PPAR in an vitro-
ligand assay [25]. Palmitate was able to restore adipogenic gene expression however, it only 
resulted in a slight increase in lipid accumulation (Fig2A,C-D). While we saw this restoration of 
PPARy and FABP4 expression upon treatment with palmitate, this may just be the result of lipid 
droplet formation from palmitate accumulation and not necessarily indicate an increase in 
lipogenesis, especially since this increase in lipid accumulation is not equal to that of control 
cells. Interestingly, palmitoyl-CoA acts similarly to SA by binding to the BC domain of ACCs 
promoting their dissociation and inhbition of ACCs and consequently increasing FAO [33]. 
The role of ACC1 in de novo lipogenesis  is well established [2] and ACC1 is highly expressed 
in adipose tissue [34]. ACC2 is expressed abundantly in skeletal muscle while mouse adipose 
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tissue has low levels of ACC2 [34], the ACC isoform responsible for production of malonyl-
CoA that inhibits CPTI, the enzyme responsible for catalyzing the rate limiting step in fatty acid 
oxidation of long chain fatty acids [4]. Increases in fatty acid oxidation upon treatment with SA 
have previously been observed in liver HepG2 cells, and prostate cancer cell lines in LNCaP and 
PC-3M cells [35] [36].  Interestingly, we found a ~3- and ~2-fold increase in fatty acid oxidation 
with both chronic and acute treatment of SA, respectively (Fig.3) and this increase is comparable 
to those achieved in other cell lines, ~3-fold in HepG2 cells and ~2-fold in LNCaP cells [35,36]. 
These results suggest that fatty acid oxidation is at least partially responsible for the lack of 
triacylglycerol accumulation in SA treated cells.  
Impairment of triacylglycerol storage and inhibition of de novo lipogenesis impairs insulin 
sensitivity [27] and promoting glucose uptake into adipose tissue prevents diabetes in mice with 
transgenic enhancement of the insulin-sensitive glucose transporter, GLUT4(Shepherd, J. biol. 
Chem, 1993). Because we saw a decrease in other adipogenic target genes and lipid 
accumulation, we investigated whether GLUT4, another transcriptional target of PPAR and 
glucose uptake is affected by SA administration. Treatment with SA decreased GLUT4 mRNA 
expression and was restored to levels of the control with palmitate supplementation. However, 
we found that insulin-mediated glucose uptake was unaffected in 3T3-L1 cells treated with SA 
upon insulin (Figure 4A,B). Upon stimulation by insulin, GLUT4 is translocated to the plasma 
membrane independently of transcription and translation[37] and this may explain why glucose 
uptake is unaffected by SA treatment even though there is a change in GLUT4 mRNA 
expression. This is particularly important to note as adipose tissue-GLUT4 depletion leads to 
insulin resistance in liver and muscle tissue [38] even though adipose tissue is not the primary 
tissue responsible for glucose disposal [39]. Our glucose uptake results are in agreement with 
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those results obtained from animal studies. Mice fed high fat diets supplemented with SA 
maintained insulin sensitivity as observed by insulin-stimulated disposal rates and glucose 
infusion rates similar to mice fed a chow diet [16]. 
Inhibition of adipogenic genes and lipid accumulation by SA only occurred if SA was 
continuously added to the media at the beginning of differentiation. Surprisingly, though at day 
16 of SA administration, PPAR and FABP4 gene expression were elevated compared to control 
cells and cells that had had SA removed at either day 8, 10 or 12.  This may have been the cell’s 
attempt to overcome SA treatment and promote triacylglycerol storage. Even when SA was 
administered for more than 16 days, upon its removal, the cells would resume differentiation. 
This has been reported previously with the dual ACC inhibitor, CABI [31]. Adipogenesis is a 
highly regulated process and involves a number of transcription factors and signaling pathways 
[40]. We suspect that even though PPAR is downregulated, there may be other factors that are 
unaffected by SA inhibition. The CCAAT-enhancer-binding protein beta (C/EBP) is found to 
be crucial for adipogenesis in immortalized preadipocyte line but may not be necessary for 
mouse embryonic fibroblasts (MEFs) [41]. We found that C/EBP mRNA expression is 
unaffected by SA treatment (Supplemental Fig. 1) and this may explain in part why 3T3-L1 
cells proceed through adipogenesis upon removal of SA. 
If SA was administered in later stages of differentiation, there was no change in the size or 
amount of lipid droplets and the adipogenic genes remain unchanged. Work by Camp et al. 
demonstrated that a novel potent antagonist, PD068235 was unable to cause dedifferentiation of 
mature adipocytes indicating that PPAR activation is minimal in differentiated adipocytes [42].  
We tested the effect of differentiating cells with rosiglitazone, a PPAR agonist, and insulin and 
observed the effects on adipogenesis while simultaneously administering SA.  Surprisingly, we 
98 
 
found that PPAR and FABP4 gene expression were increased despite treatment with SA.  
Administering SA in combination with palmitate resulted in even more dramatic increase in 
PPAR and FABP4. This contrasts with the results we obtained when administering SA in 3T3-
L1 cells that are differentiated with the classic differentiation cocktail of insulin, IBMX, and 
dexamethasone where SA treatment decreased adipogenic markers. These differences in 
adipogenic gene expression in cells differentiated by the two differentiation methods indicate 
that what we have observed may not necessarily be inhibition of adipocyte differentiation but 
rather an altered adipocyte phenotype that prevents lipid accumulation.  
We report here that inhibition of ACCs by SA decreases adipogenic gene expression and lipid 
accumulation. Fatty acid oxidation is at least partially responsible for the lack of lipid droplet 
accumulation. Treatment with SA maintains insulin sensitivity in these cells despite a reduction 
in GLUT4 mRNA translocation. Upon removal of SA, 3T3-L1 cells proceed through 
adipogenesis. We propose that ACC inhibition alters lipid metabolism but not adipogenesis in 
3T3-L1 cells.  
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Table 1. PCR primers  
Gene  Primers         
   
Mouse 18S ribosomal RNA      
   
 
Mouse peroxisome proliferator-activated 
receptor gamma transcript variant 2(PPARγ) 
FWD  5'-CTGAGAAACGGCTACCACATC-3' 
REV   5'-GCCTCGAAAGAGTCCTGTATTG-3' 
 
FWD  5'-AGATTCTCCTGTTGACCCAGAGCA-3' 
REV   5'-ATTCCGAAGTTGGTGGGCCAGAAT-3' 
 
 
 
 
 
Mouse fatty acid binding protein 4 (FABP4) FWD  5'-ATGAAATCACCGCAGACGACAGGA-3' 
REV   5'-TGTGGTCGACTTTCCATCCCACTT-3' 
 
 
Mouse glucose transporter 4 (GLUT4)  FWD  5'-GGAGGGAGCCTTTGGTATTT-3' 
REV  5'-CAGCACAGGACACTCATCTT-3' 
 
 
 
Mouse CCAAT-enhancer binding protein beta 
(C/EBPβ) 
FWD  5'-CTTGATGCAATCCGGATCAAAC-3' 
REV  5'-CCCGCAGGAACATCTTTAAGT-3' 
 
 
 
Mouse acetyl-CoA carboxylase 1 (ACC1) FWD  5'-TAACAGAATCGACACTGGCTGGCT-3' 
REV  5'-ATGCTGTTCCTCAGGCTCACATCT-3' 
  
 
Mouse acetyl-coA carboxylase 2 (ACC2) FWD  5'-ACCCACTGTCTTCCAATGACACCT-3' 
REV  5'-TCAGCTGTCTCTTGATGTGTGCCT-3' 
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Figure 1. Soraphen A decreases lipid accumulation and adipogenic gene expression. A) 3T3-L1 
cells were treated with a DMSO vehicle control (a) or either 100 nM (b) or 1 μM (c) SA for 8 
days and cells were fixed at Day 8 and stained with Oil Red O. Gene expression of B) PPARγ 
and C) FABP4 was measured at day 4 and 8. mRNA expression was normalized to 18srRNA and 
101 
 
calculated as % of control (2-way ANOVA *p<0.05).  Results are representative of 3 different 
experiments. 
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Figure 2. Palmitate rescues expression of PPARγ and FABP4 and partially restores lipid droplet 
accumulation. A) 3T3-L1 cells were treated with SA for 8 days (a) or SA and 100µM or 200μM 
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palmitate. Cells were fixed at Day 8 and stained with Oil Red O and absorbance at 490nM was 
measured. Gene expression of B) PPARγ and C) FABP4 upon treatment with or without SA 
and/or palmitate treatment. mRNA expression was normalized to 18srRNA and calculated as % 
of control (One way ANOVA**p<0.01). D) Cell viability. Results are representative of 3 
different experiments. **p<0.01;*p<0.05, significantly different from control.  
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Figure 3. Fatty acid oxidation is increased in SA treated cells. A) 3T3-L1 cells were 
differentiated for 7 days and treated with or without 100nM SA beginning at Day 0 or SA 1μM 
for 12 hours prior to addition of either BSA or 50μM/0.5μCi [9,10-3H]-palmitate for 2 hours.  
Samples were processed as described and 
3
H-labeled H2O was quantified by liquid scintillation 
counting. Results were calculated as counts per minute/ug protein and expressed as % of control. 
Results are representative of 5 different experiments. ***p<0.001;**p<0.01;*p<0.05, 
significantly different from control.      
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Figure 4. Insulin sensitivity is maintained in SA treated cells.  A) GLUT4 mRNA expression 
upon treatment with or without SA and/or palmitate treatment. mRNA expression was 
normalized to 18srRNA and calculated as % of control. B) Glucose uptake assays. 3T3-L1 cells 
were differentiated for 7 days and treated with or without 100nM SA beginning at Day 0 or SA 
1μM for 12 hours prior to addition of 2-[1,2-3H(N)]deoxy-d-glucose [0.05Ci/mL] for 90 
minutes. Samples were processed as described and quantified with a liquid scintillation counter. 
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Results were calculated as counts per minute/μg protein and expressed as % of control. Results 
are representative of 3 different experiments.  
  
107 
 
 
 
Figure 5. Time course additions of SA. Cells were treated with SA for 8, 10, 12, 0r 16 days 
followed by sample collection after Day 16.  Gene expression of A) PPARγ or B) FABP4 from 
cells treated for SA for various times.  C) 3T3-L1 cells were treated with either 100 nM or 1 μM 
SA beginning at 8 days post-differentiation and fixed at Days 12.  Cells were stained with ORO 
and viewed at 4x using a Nikon Ti-S Inverted Fluorescence Microscope.         
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Figure 6. Rosiglitazone rescues adipogenic gene expression despite treatment with SA. Cells 
were differentiated with a rosiglitazone/insulin cocktail and treated with either 100 nM SA with 
or without 200 μM palmitate. Gene expression of A)PPARγ B)FABP4 C)GLUT4 was quantified 
using RT-qPCR. mRNA expression was normalized to 18srRNA and calculated as % of control 
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(One-way ANOVA p<0.0001 for PPARγ and FABP4; GLUT4 n.s.).Results are representative of 
3 different experiments.****p<0.0001;***p<0.001; **p<0.01;*p<0.05, significantly different 
from control. 
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Supplemental Figure 1. Gene expression of C/EBPβ upon treatment with or without SA and/or 
palmitate treatment. mRNA expression was normalized to 18SrRNA and calculated as % of 
control. Results are representative of 3 different experiments.  
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Outlook 
We have demonstrated that inhibitors designed against HLCS work in vitro.  However, in a cell 
culture system we were unable to observe a decrease in biotinylated carboxylases and saw an 
increase in carboxylase biotinylation. These results indicate the need for further studies with 
respect to the development of HLCS inhibitors.  However, this could prove challenging given the 
difficulty in developing inhibitors that selectively target the mammalian HLCS over the bacterial 
homologs and vice versa.  To date, only one class of inhibitors specific to Staphylococcus aureus 
biotin protein ligase has been developed [1].  The value of HLCS inhibitors is that they provide a 
means by which to study the impact of HLCS on gene regulation and enzyme activity within a 
cellular context.  Given that there is no living HLCS null individual and that mutations in HLCS 
can present with severe symptoms and possibility of fatality, using these inhibitors in animals or 
humans to study HLCS within a mammalian system would most likely be dangerous [2-4]. To 
validate previous in vitro observations and perform animal studies that are currently not feasible, 
development of a conditional HLCS knockout (KO) mouse model will allow us to investigate 
HLCS interactions in vivo. We are in the process of creating a conditional HLCS KO mouse in 
which expression can be controlled both spatially and temporally. These mice will allow us to 
knock out HLCS gene in specific tissues at defined developmental stages and investigate the 
impacts of HLCS on gene regulation, and genome stability, and HLCS-dependent enzyme 
activity under controlled conditions.  
The ACCs continue to be an active area of research as drug targets in the treatment of metabolic 
disorders [5].  Animal studies have demonstrated that treatment with Soraphen A prevents mice 
from diet induced obesity and weight gain[6]. Here we report that Soraphen A, an inhibitor of 
eukaryotic ACC activity prevents adipogenic gene expression and lipid accumulation in 3T3-L1 
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cells. However, it is unknown whether or not these results carry over to humans. It would be 
important to first establish if lipogenesis is blocked upon treatment with Soraphen A or other 
ACC inhibitors in human adipogenic stem cells. There are other considerations to take into 
account as well. Adipose tissue is not the primary site of de novo lipogenesis upon high fat 
feeding in humans [7]. Fat-specific fatty acid synthase knockout mice demonstrate decreased 
adipogenesis and increased thermogenesis [8].   It is unknown if a similar outcome would be 
observed upon inhibition of lipogenic genes in human adipose tissue.  Additionally, it is 
unknown how ACC inhibitors would act in humans. The ACCs are present in multiple tissues 
and serve different roles depending on the tissue.  Administering these inhibitors in vivo could 
have detrimental effects if the distribution of ACC inhibitors is nonspecific.  These questions 
demonstrate the need for more research into the effects of ACC inhibitors in human adipogenic 
stem cells and in vivo human studies.         
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Appendix 
-Raw data for each chapter 
Chapter I. 
Inhibition of HLCS by biotin β-ketophosphonate 
Table 1. Dose response curve of biotin β-ketophosphonate 
β-ketoP Gel  densitometry     
0µM 172.49 111.94 56.37 110.45 
50µM 61.80 40.00 40.38 78.77 
100µM 53.63 29.38 36.89 67.29 
250µM 33.59 18.35 27.86 57.44 
500µM  13.76 11.53 15.20 32.51 
 
Table 2. Competitive inhibition assays w/ biotin β-ketophosphonate 
No β-
ketoP         
Biotin 
conc.  Gel densitometry     
0µM 19.32 14.94 5.20 22.11 
10µM 589.01 469.77 482.27 497.00 
20µM 608.30 523.34 475.31 436.87 
40µM 436.74 387.80 516.05 480.83 
80µM 480.39 463.88 519.09 530.11 
160µM 629.16 438.98 516.77 573.15 
320µM 524.91 529.18 513.16 489.21 
     
W/ β-
ketoP         
Biotin 
Conc.  Gel densitometry     
0µM 7.67 4.68 9.02 1.64 
10µM 85.50 94.56 80.18 12.83 
20µM 180.18 114.23 172.13 30.59 
40µM 191.93 200.85 254.83 101.83 
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80µM 369.72 232.02 380.98 365.46 
160µM 451.58 378.07 453.76 611.73 
320µM 485.12 527.53 516.35 498.39 
 
Inhibition of HLCS by biotin β-hydroxyphosphonate 
Table 3. Dose response curve of biotin β-hydroxyphosphonate 
βhydroxyP Gel densitometry     
0µM 143.29 87.64 207.85 297.98 
50µM 148.12 64.16 164.16 237.01 
100µM 97.43 56.22 111.82 222.16 
250µM 66.73 38.28 70.72 144.53 
500µM  55.73 37.58 47.96 73.08 
 
Table 4. Competitive inhibition assays w/ biotin β-hydroxyphosphonate 
No β-
hydroxyP         
Biotin conc. Gel densitometry     
0µM 13.12 16.56 28.29 12.87 
10µM 384.34 319.61 576.00 407.24 
20µM 380.12 357.86 444.50 448.87 
40µM 380.70 338.24 530.13 445.51 
80µM 399.70 317.41 498.36 437.09 
160µM 381.88 303.64 486.62 478.20 
240µM 436.39 323.15 661.25 524.07 
320µM 536.18 333.53 719.23 659.66 
     
w/β-hydroxyP         
Biotin conc. Gel densitometry     
0µM 4.90 8.08 12.00 3.28 
10µM 40.78 72.35 50.03 38.71 
20µM 56.49 123.84 81.37 79.02 
40µM 111.99 152.42 156.73 97.89 
80µM 210.64 198.26 218.12 159.64 
160µM 260.63 277.19 279.76 243.84 
240µM 346.21 313.64 295.54 285.58 
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320µM 491.75 335.69 291.37 287.25 
 
Inhibition of HLCS by biotinol-5’-AMP 
Table 5. Dose response curve of biotinol-5’-AMP 
Bio-5'-AMP Gel densitometry   
0µM 125.91 290.11 112.77 
50µM 11.37 44.42 14.47 
100µM 6.11 18.66 3.38 
250µM 5.34 8.97 2.56 
500µM  2.66 5.51 2.20 
 
Table 6. Competitive inhibition assays w/ biotinol-5’-AMP 
Chapter II. 
Table 7. Effect of grape leaf extract on body fat mass in male and female Drosophila 
melanogaster brummer mutants 15828. 
Control and experimental Groups 
of Brummer flies 
Results in mg of lipid/ grams of fly weight 
1 2 3 4 
Control-Male 31.87 31.27 32.4 13.35 
Grape leaf extract 0.5% Male 19.00 3.01 18.63 10.90 
Grape leaf extract 10% Male 10.28 12.36 9.21 1.55 
Control-Female 29.91 31.33 39.21 29.26 
Grape leaf extract 0.5% Female 18.46 14.46 11.44 12.58 
Grape leaf extract 10% Female 10.1 8.65 17.71 17.93 
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Table 8. Effect of grape leaf extract on body fat mass in male and female Drosophila 
melanogaster brummer mutants 15959. 
Control and experimental Groups 
of Brummer flies 
Results in mg of lipid/ grams of fly weight 
1 2 3 4 
Control-Male 9.43 10.38 14.38 12.43 
Grape leaf extract 0.5%-Male 6.54 7.98 4.65 4.70 
Grape leaf extract 10%-Male 4.08 6.68 6.76 5.85 
Control-Female 6.89 10.96 11.15 7.41 
Grape leaf extract 0.5%-Female 6.94 8.31 6.82 5.35 
Grape leaf extract 10%-Female 5.83 8.16 6.80 7.33 
 
Table 9. Effect of piceid on body fat mass in male and female Drosophila melanogaster 
brummer mutants 15828. 
Control and experimental Groups 
of Brummer flies 
Results in mg of lipid/ grams of fly weight 
1 2 3 4 
Control-Male 5.91 2.19 3.95 2.81 
Piceid 0.012 µM-Male 1.92 1.28 4.90 
Piceid 0.12 µM-Male 0.68 0.44 0 
Control-Female 9.38 9.13 12.26 11.60 
Piceid 0.012 µM-Female 7.04 6.40 8.21 
Piceid 0.12 µM-Female 11.03 7.46 7.87 
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Table 10. (Chapter III) Effect of soraphen A on body fat mass in male and female Drosophila 
melanogaster brummer mutants 15828. 
Control and experimental Groups 
of Brummer flies 
Results in mg of lipid/ grams of fly weight 
1 2 3 4 
Control-Male 2.27 3.43 2.28 5.14 
Soraphen A 5 µM-Male 0.84 0.49 1.27 1.04 
Control-Female 7.36 5.59 8.97 6.69 
Soraphen A 5 µM-Female 0.22 1.39 1.10 1.37 
 
Chapter III 
Table 11. Adipogenic gene expression 
FABP4 mRNA 
expression RT-PCR Ct values normalized by  
  M18SrRNA     
Treatment  Repeat  1 2 3 
Day 0 Control  1.00 1.00 1.00 
Day 4 Control   113.79 76.66 311.41 
Day 4 Soraphen A 
100nM  125.41 43.82 138.15 
Day 4 Soraphen A 1µM  89.78 38.24 113.87 
Day 8 Control  93.11 46.75 272.13 
Day 8 Soraphen A 
100nM  70.04 75.46 251.33 
Day 8 Soraphen A 1μM    56.44 42.24 217.88 
     
     
PPARγ mRNA 
expression RT-PCR Ct values normalized by  
  M18SrRNA     
Treatment  Repeat  1 2 3 
Day 0 Control  1.01 1.00 1.01 
Day 4 Control   151.94 118.34 135.14 
Day 4 Soraphen A 
100nM  146.05 80.90 113.47 
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Day 4 Soraphen A 1µM  92.05 50.45 71.25 
Day 8 Control  343.66 154.71 249.18 
Day 8 Soraphen A 
100nM  190.04 172.48 181.26 
Day 8 Soraphen A 1μM    168.23 114.83 141.53 
 
Table 12. Cell viability of cells treated with or without SA.   
Treatment  #Live cells 
#Dead 
cells 
Control 1920000 48000 
  1900000 216000 
  1,488,000 408000 
SA 100nM 1180000 72000 
  1180000 72000 
  576,000 168000 
SA 1uM 1030000 48000 
  912,000 144,000 
  936,000 120000 
 
Table 13. Adipogenic gene expression is rescued upon treatment with palmitate.  
PPARy RT-PCR Ct values normalized    
  
to 18SrRNA 
control     
Treatment Repeat  1 2 3 
Day 0 Ctrl   1.00 1.00 1.00 
Day 8 Ctrl  448.31 241.95 989.34 
Day 8 Sa 100nM SA  31.18 94.60 195.98 
Day 8 +100nM SA +100uM Pal   123.98 133.77 273.45 
Day 8 +100nM SA +200uM Pal   462.53 284.21 639.54 
     
     
     
FABP4 RT-PCR Ct values normalized    
  
to 18SrRNA 
control     
Treatment Repeat  1 2 3 
Day 0 Ctrl   1.00 1.00 1.00 
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Day 8 Ctrl  576.09 334.33 816.83 
Day 8 Sa 100nM SA  54.59 54.59 212.97 
Day 8 +100nM SA +100uM Pal   148.23 164.68 260.49 
Day 8 +100nM SA +200uM Pal   906.22 323.29 691.47 
      
     
Table 14. Cell viability of 3T3-L1 treated with or without SA or SA and palmitate 
Treatment  #Live  # Dead 
Ctrl No SA 1296000 96000 
  936000 216000 
  2040000 336000 
Ctrl +SA 100nM 1488000 72000 
  600000 144000 
  1440000 264000 
SA100nM  and 
Pal100uM 1464000 96000 
  1464000 144000 
  2112000 216000 
SA100nM  and 
Pal200uM 1248000 192000 
  1104000 72000 
  2160000 192000 
 
Table 15. Oil Red O quantitation 
Treatment  Absorbance at 490nM       
Control DMSO 0.240 0.187 0.199 0.199 0.206 
SA 100nM 0.053 0.071 0.060 0.063 0.062 
SA 1uM 0.066 0.047 0.051 0.064 0.057 
SA 100nM Pal 200uM 0.104 0.097 0.075 0.083 0.090 
SA 100nM Pal 100uM 0.074 0.084 0.095 0.127 0.095 
 
Table 16. Fatty acid oxidation upon treatment with SA. 
  Counts per minute normalized to total protein concentration   
Treatment  Repeat   1   2   3   
Control No SA + 50uM Pal    14.14 13.67 10.01 9.69 17.18 16.65 
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SA 100nM @ Day 0 + 50uM 
Pal    32.70 31.70 28.61 27.79 52.78 51.05 
SA 1uM + 50uM Pal    45.22 43.80 45.04 43.65 38.92 37.71 
Etomoxir + 50uM Pal    8.93 8.64 6.09 5.90 9.89 9.56 
Control No SA + BSA    0.60 0.59 0.63 0.62 0.17 0.17 
SA 100nM @ Day 0 + BSA    1.44 1.40 1.35 1.32 1.11 1.09 
SA 1uM @ Day 0 + BSA   1.27 1.22 0.54 0.52 0.26 0.25 
Etomoxir + BSA   0.36 0.34 1.62 1.57 0.15 0.14 
    4   5     
Control No SA + 50uM Pal   5.33 5.16 6.69 6.50   
SA 100nM @ Day 0 + 50uM 
Pal   18.72 18.18 19.25 18.68   
SA 1uM + 50uM Pal   9.22 8.94 7.97 7.71   
Etomoxir + 50uM Pal   3.93 3.81 3.59 3.48   
Control No SA + BSA          
SA 100nM @ Day 0 + BSA          
SA 1uM @ Day 0 + BSA         
Etomoxir + BSA             
 
Table 17. GLUT4 expression is rescued upon treatment with palmitate. 
  RT-PCR Ct values normalized    
GLUT4 to 18SrRNA control     
Treatment  Repeat  1 2 3 
Day 0 Ctrl   1.05 1.05 1.05 
Day 8 Ctrl  355.53 31.45 555.94 
Day 8 Sa 100nM SA  90.37 1.86 164.85 
Day 8 +100nM SA +100uM Pal   102.67 19.07 220.55 
Day 8 +100nM SA +200uM Pal   646.03 15.86 494.99 
 
Table 18. Glucose uptake assays 
  Counts per minute normalized to total protein concentration   
Treatment  Repeat  1   2   3   
Control No SA + Insulin   2.63 2.53 1.93 1.86 1.62 1.55 
SA 100nM + Insulin  2.78 2.67 1.59 1.53 1.97 1.91 
SA 1uM + Insulin   2.56 2.46 1.73 1.65 1.45 1.39 
Control No SA   1.82 1.74 1.13 1.10 0.87 0.84 
SA 100nM   2.25 2.19 1.78 1.72 1.23 1.18 
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Sa 1uM    1.74 1.68 1.28 1.23 1.22 1.18 
 
Table 19. Adipogenic gene expression in 3T3-L1 cells upon treatment with SA in late stages of 
differentiation. 
PPARγ     
RT-PCR Ct values normalized to 18SrRNA 
control       
Treatment        Repeat  1 2 
Day 0 -undifferentiated 
cells        1.01 1.01 
Ctrl DMSO 0.3uL Coll. Day 
16     3.45 19.66 
Ctrl SA 100nM (0.3ul) Coll. Day 16    151.27 16.71 
SA 100nM (0.3ul) Start Day 0, stop Day 8, Coll. Day 16  11.51 4.15 
SA 100nM (0.3uL) Start Day 0, stop Day 10, Coll. Day 16  4.73 3.68 
SA 100nM (0.3uL) Start Day 0, stop Day 12, Coll. Day 16   24.70 3.08 
        
        
        
FABP4     
RT-PCR Ct values normalized to 18SrRNA 
control       
Treatment        Repeat  1 2 
Day 0 -undifferentiated 
cells        1.01 1.01 
Ctrl DMSO 0.3uL Coll. Day 
16     6.25 9.69 
Ctrl SA 100nM (0.3ul) Coll. Day 16    270.23 135.35 
SA 100nM (0.3ul) Start Day 0, stop Day 8, Coll. Day 16  47.80 24.71 
SA 100nM (0.3uL) Start Day 0, stop Day 10, Coll. Day 16  8.04 9.76 
SA 100nM (0.3uL) Start Day 0, stop Day 12, Coll. Day 16   14.77 14.28 
 
Table 20. C/EBPβ gene expression upon treatment with SA or SA and palmitate 
c/EBPβ RT-PCR Ct values normalized    
  to 18SrRNA control     
Treatment  Repeat  1 2 3 
Day 0 Ctrl    1.03 1.00 1.03 
Day 8 Ctrl   2.94 0.61 0.67 
Day 8 Sa 100nM SA   3.10 2.28 0.74 
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Day 8 +100nM SA +100uM Pal    1.25 0.82 0.18 
Day 8 +100nM SA +200uM Pal   0.72 0.45 0.61 
 
